COPE Advertising options


PBL Assay Science COGITO ERGO COPE ADVERTISING SPACE http://immunospot.com/index.php?id=74

COPE Homepage Bottom of page Previous entry:
mast cell protease-7-like
Next entry:
mast cell tryptase
Random entry:
Impressed-by-contrast cells
Search COPE:

Please donate

If you find COPE helpful,
please show your appreciation
by donating what you can afford.

mast cells

common abbreviations:

BMMC [bone marrow-derived mast cells]
PMC [peritoneal mast cells]


Mast cells, also being referred to as mastocytes, arise from a multipotent CD34(+) precursor in the bone marrow (Nakahata and Toru 2002; Austen and Boyce, 2001) that also express kit (receptor for mast cell growth factor or stem cell factor SCF), and IgG receptors (Fc-gamma R2). These precursors do not express high affinity IgE receptors (Fc-epsilon R1). In the peripheral blood they have the appearance of agranular cells that resemble monocytes. These immature mast cells assume their typical granular morphology when they have migrated into tissues. These cells also express Fc-epsilon R1 and stop expressing CD34 and Fc-gamma R2. For a genetic locus affecting mast cell generation see also: W/Wv mice.

Mast cells usually do not normally circulate in the blood stream. They are sessile cells found in small numbers in the connective tissue of all organs. The dermal layer of skin (around blood vessels and nerves) contains many mast cells. Increased numbers of mast cells are found in many pathological conditions. Mast cells have been considered the tissue equivalent of circulating basophils. They probably arise from common precursor cells in the bone marrow but there is no evidence that mature basophils differentiate into mast cells. Mast cells may retain their proliferative potential after differentiation or degranulation and can recover the original morphology.

Depending upon their tissue location, mast cells may differ morphologically and biochemically. Subclasses of mast cells can be differentiated by their ability to express specific secretory granule-localized proteases and proteoglycans. Granule-associated tryptase and chymase (as well as carboxypeptidase A3 and cathepsin G) is found in mast cells in the skin, intestinal submucosa, breast and axillary lymph nodes contain (these cells are designated MCTC mast cells or TC mast cells). Most mast cells in the lung and intestinal mucosa produce only tryptase (these cells are designated MCT mast cells or T mast cells) (Irani et al, 1991; 1986; Schechter et al, 1990). Oskeritzian et al (2005) have reported that MCTC mast cells express CD88 antigen and can be distinguished from MCT mast cells,which do not express the antigen. Some mast cell populations in axillary lymph nodes, lungs, bowel mucosa and submucosa may express only chymase. Transplantation of mast cells from one anatomical site into a new environment usually leads to the acquisition of the phenotypeobserved in the second environment.

Mast cells play a central role in immediate allergic reactions by releasing potent mediators. They participate also in host responses to parasites and neoplasms, angiogenesis, tissue remodeling and wound healing, as well as immunologically non-specific inflammatory and fibrotic conditions. These mediators can have local and systemic effects and can act on the vasculature, smooth muscle, connective tissue, mucous glands and inflammatory cells. Mast cells contain special cytoplasmic granules that store inflammatory mediators. The content of mast cell granules varies between species and in some pathological conditions. Preformed mediators within secretory granules are secreted upon cell activation and include histamine, proteoglycans and neutral proteases. Newly generated mediators consist of arachidonic acid metabolites and multifunctional cytokines. The process of extracellular release of these mediators is known as degranulation. Degranulation can be induced by a variety of immune and nonimmune mechanisms and may involve secreted or membrane-bound cytokines as well as direct cell-to-cell interactions. Different stimuli, including mediators secreted or presented by nearby cells, may affect the amount and type of mediators released from mast cells or the expression of early response genes, with individual factors, alone or in combination exerting a different spectrum of stimulatory, costimulatory, or regulatory effects on mast cell functions. Some cytokines and their receptors are expressed also constitutively. Responses to stimuli and pharmacologic agents may vary, depending upon the anatomical sites. Some mediators are known to stimulate skin mast cell mediator release, but have little effect on lung and intestinal mast cells in vitro. IgE dependent immune mechanisms are caused by binding of IgE to high-affinity receptors (Fc-epsilon R1). IgE independent mechanisms involve activation of C5a receptors. In addition, a variety of other stimuli can elicit degranulation.

Studies in vitro and in vivo have demonstrated that these cells have the capacity to express many different bioactive mediators, which may be engaged in autocrine, paracrine or endocrine interactions that can affect many other cell types (Okayama et al, 1995; KrŸger-Krasagakes and Czarnetzki, 1995; Galli and Wershil, 1995; Galli et al, 1991). Expression of most of these mediators is subject to modulation by cytokines, growth factors, hormones, cell activation, differentiation, or transformation stage, disease conditions. Expression capacities may depend also upon the differentiation stage of the cells or their anatomical location. Different properties also depend, at least in part, on the source of progenitor cells (derived, for example, from fetal liver, cord blood, peripheral blood, adult bone marrow) and some of the factors may be expressed transiently only during development. Regulation in vitro of human mast cell growth and function differs from regulation of rodent mast cells (Kirshenbaum et al, 2000). Lora et al (2003) have reported the results of gene expression profiling experiments in human mast cells, describing sets of genes expressed after cell activation in response to SCF, IL4, IL5, and IL9.

Mast cells have been shown to possess the capacity to express the proteins listed below. Please note the following general observations, which practically apply to all cell types: expression may be influenced by tissue localization, may occur only in discrete subpopulations of cells, may vary between established cell lines, primary cells, embryonic cells, mature cells, fully differentiated cells, activated cells, non-activated cells or growth conditions (confluent vs. sparse cultures), may be influenced by various disease states (including cancer environment), and may differ between species.
Note also: expression profile information lists entities only for which there is an entry in COPE or one of its subdictionaries.

The meaning of ¥ and ¥¥ is as follows: ¥ factor/protein is expressed; ¥¥ receptor (or, in some instances, binding sites) for this factor/protein is expressed. For further explanations concerning format, "hidden" information, and/or ambiguities see my remarks in the entry cell types.


¥ 4-1BB (CD137, CDw137, Ly63, lymphocyte antigen 63, ILA, induced by lymphocyte activation, TNFRSF9, TNF receptor superfamily member 9) (Nakajima et al, 2002; Nakae et al, 2006; Stelekati et al, 2009)

¥ Activin A (EDF, erythroid differentiation factor, FRP, Follicle stimulating hormone releasing protein, Restrictin-P, WEHI-MIF, WEHI mesoderm inducing factor, activin-beta-A, INHA, inhibin-alpha, Inhibin-beta-A, INHBA ) (Funaba et al, 2003)
¥¥ AcSDKP (N-acetyl-seryl-aspartyl-lysyl-proline, acetyl-N-Ser-Asp-Lys-Pro, Seraspenide, Goralatide, thymosin-beta-4) receptors (Leeanansaksiri et al, 2004; Wycz—lkowska et al, 2007)
¥¥ Activin A (EDF, erythroid differentiation factor, FRP, Follicle stimulating hormone releasing protein, Restrictin-P, WEHI-MIF, WEHI mesoderm inducing factor, activin-beta-A, INHA, inhibin-alpha, Inhibin-beta-A, INHBA ) receptors (Funaba et al, 2003)
¥ ADAM10 [disintegrin and metalloprotease domain 10, MADM, mammalian disintegrin metalloprotease, CDw156c, CD156c, kuzbanian, Kuzbanian homolog, KUZS, KUZL, EC3.4.24.81] (Tsuchiya S et al, 2009)
¥ adenosine receptors (Feoktistov et al, 2003)
¥ Alpha-B-crystallin (crystallin-alpha B, crystallin-alpha 2, alphaBC, CRYAB, CRYA2, REN-27, NY-REN-27, hspB5, heat shock protein beta-5) (Tsuchiya S et al, 2009)
¥¥ alpha-MSH (melanocyte stimulating hormone-alpha, alpha-melanotropin, alpha-melanocortin, melanotropin, POMC, proopiomelanocortin) receptors (Adachi et al, 1999; GrŸtzkau et al, 2000; Teofoli et al, 1999)
¥ amphiregulin (AR, AMR, AREG, CRDGF, colorectum cell-derived growth factor, KAF, keratinocyte-derived autocrine factor, SDGF, schwannoma-derived growth factor, AURA9, augmented in rheumatoid arthritis 9) (Tsuchiya S et al, 2009)
¥ angiopoietin-1 (Ang-1, ANGPT1, KIAA0003) (Nakayama et al, 2004)
¥ angiopoietin-2 (Ang-2, ANGPT2) (Feoktistov et al, 2003)
¥ Angiopoietin-like-2 (ANGPTL2, ARP-2, angiopoietin-related protein-2) (Tsuchiya S et al, 2009)
¥ Angiopoietin-related growth factor (AGF, ARP-5, angiopoietin-related protein-5, ANGPTL6, angiopoietin-like-6) (Oike et al, 2003)
¥ Annexin-1 (Annexin A1, ANX1, ANXA1, lipocortin-1, LPC1, LCT1, LC1, Lipo1, macrocortin, renocortin, lipomodulin, GIF, glycosylation inhibiting factor, CB9, chromobindin-9, calpactin-2) (Damazo et al, 2006; Kim et al, 2008; Oliani et al, 2000; Reynolds et al, 2007; Sena et al, 2006; Silistino-Souza et al, 2007; Tasaka et al, 1994)
¥¥ Annexin-1 (Annexin A1, ANX1, ANXA1, lipocortin-1, LPC1, LCT1, LC1, Lipo1, macrocortin, renocortin, lipomodulin, GIF, glycosylation inhibiting factor, CB9, chromobindin-9, calpactin-2) receptors (Silistino-Souza et al, 2007)

¥ B7-H1 (B7 homolog-1, PDCD1L1, PDCD1 Ligand 1, PDL1, programmed death-1 ligand 1, CD274) (Nakae et al, 2006)
¥ BAG-1 (BCL2-associated athanogene-1, BAG family molecular chaperone regulator 1, RAP46, receptor-associating protein 46 kDa) (Tsuchiya S et al, 2009)
¥ BAG-2 (BCL2-associated athanogene-2, BAG family molecular chaperone regulator 2) (Tsuchiya S et al, 2009)
¥ BAIAP2 (BAI-associated protein 2, brain-specific angiogenesis inhibitor 1-associated protein 2) (Tsuchiya S et al, 2009)
¥ basigin (BSG, CD147, EMMPRIN, extracellular matrix metalloproteinase inducer, 5A11, CE-9, Collagenase stimulatory factor, gp42, HT7, M6, neurothelin, Oka blood group antigen, OX47) (Wimazal et al, 1999; Krauth et al, 2005; Ghannadan et al, 1998; Tsuchiya S et al, 2009)
¥ BCL2-like-2 (BCL2L2, c98, BCLw, KIAA0271) (Tsuchiya S et al, 2009)
¥ BDNF (Brain-derived neurotrophic factor, Abrineurin) (Tam et al, 1997; Zochodne and Cheng, 2000)
¥ Beta-2-Microglobulin (Beta-2-M, B2M, Ly-m11, BDGF-2, bone-derived growth factor-2, CRG-8, cytokine responsive gene-8, Thymotaxin, GIP-2, granulocyte inhibitory protein, AURA54, augmented in rheumatoid arthritis 54) (Tsuchiya S et al, 2009)
¥ bFGF (basic fibroblast growth factor, FGF basic, FGF-2, Fibroblast growth factor-2, FGF-beta, Fibroblast growth factor-beta, HBGF-2, heparin binding growth factor-2) and/or receptors (Ribatti et al, 2002; Qu et al, 1995, 1998; Akimoto et al, 1999; Gruber et al, 1995; Artuc et al, 2002; Reed et al, 1995; Esposito I et al, 2004)
¥¥ bFGF (basic fibroblast growth factor, FGF basic, FGF-2, Fibroblast growth factor-2, FGF-beta, Fibroblast growth factor-beta, HBGF-2, heparin binding growth factor-2) receptors (Ribatti et al, 2002; Qu et al, 1995, 1998; Akimoto et al, 1999; Gruber et al, 1995; Artuc et al, 2002; Reed et al, 1995)
¥ BMP1 (bone morphogenetic protein-1, procollagen C-proteinase, EC3.4.24.19; mammalian tolloid, mTld, tolloid, Tld) (Tsuchiya S et al, 2009)
¥ BMP4 (bone morphogenetic protein-4, bone morphogenetic protein-2B, BMP2B, DVR-4, decapentaplegic-Vg-related-4, BIP, bone-inducing protein) (Tsuchiya S et al, 2009)
¥¥ Bombesin (BN, BBS, GRP, gastrin releasing peptide, gastrin releasing hormone, Mammalian Bombesin, BLP, Bombesin-like peptide) receptors (Subramaniam et al, 2003)
¥ Btk (Bruton's tyrosine kinase, Bruton agammaglobulinemia kinase, XLA, X-linked agammaglobulinemia) (Schmidt et al, 2009)

¥ C1 inhibitor (C1INH, Serpin G1; HAE1, hereditary angioedema type 1, HAE2, hereditary angioedema type 2) (Tsuchiya S et al, 2009)
¥ C3a receptor (Hartmann et al, 1997; Legler et al, 1996)
¥¥ Calcitonin gene-related peptide (CALC1, CALCA, Calcitonin gene-related polypeptide-alpha, alpha-CGRP, CGRP-alpha, beta-CGRP, CGRP-beta, CGRP1, Calcitonin gene-related peptide-1, CGRP2, Calcitonin gene-related peptide-2, CALCB, Calcitonin gene-related polypeptide-beta, CALC2) receptors (Piotrowski and Foreman, 1986; Hoffmann P et al, 2010)
¥ CAMP (cathelicidin antimicrobial peptide, CRAMP, cathelin-related antimicrobial peptide, CAP-18, cationic antimicrobial protein of 18 kDa, LL-37, leucine-leucine-37, FA-LL-37, FALL39, PR-39, ALL-38) (Di Nardo et al, 2003)
¥¥ CAMP (cathelicidin antimicrobial peptide, CRAMP, cathelin-related antimicrobial peptide, CAP-18, cationic antimicrobial protein of 18 kDa, LL-37, leucine-leucine-37, FA-LL-37, FALL39, PR-39, ALL-38) receptors (Niyonsaba et al, 2010)
¥ caspase-6 (CASP6, MCH2, mammalian CED3 homolog-2) (Tsuchiya S et al, 2009)
¥ cathepsin L (CTSL, CAL, CATL, CTSL1, cathepsin L1, MEP, major excreted protein, IL8 converting enzyme, CP-2, cycling protein-2) (Tsuchiya S et al, 2009)
¥ caveolin-1 (CAV1, caveolae protein 1, Caveolin, CAV, caveolae protein 22 kDa, Alpha-Caveolin, beta-Caveolin, VIP21, Vesicular Integral-membrane Protein of 21 kDa, VIP21/caveolin) (Tsuchiya S et al, 2009)
¥ CCL1 (CC chemokine ligand 1, chemokine (C-C motif) ligand 1, SCYA1, I-309, TCA-3, T-cell activation-3, P500, SIS-epsilon) (Nakajima et al, 2002; Oh and Metcalfe, 1994; Selvan et al, 1994; Gilchrest et al, 2003; Ribatti et al, 2001; Wiener et al, 2008; Tsuchiya et al, 2009; Kato et al, 2009; Gombert et al, 2005)
¥ CCL2 (CC chemokine ligand 2, chemokine (C-C motif) ligand 2, GDCF, Glioma-derived monocyte chemotactic factor-2, GDCF-2, HC11, JE, LDCF, MCAF, MCP, monocyte chemoattractant protein, MCP-1, monocyte chemoattractant protein-1, SMC-CF, smooth muscle cell chemotactic factor, TDCF, tumor-derived chemotactic factors, TSG-8, tumor necrosis factor-stimulated gene sequence-8, SCYA2) (Gonzalez-Espinosa et al, 2003; Oliveira and Lukacs, 2001; Selvan et al, 1994; Ali et al, 2000; Baghestanian et al, 1997; Kulka et al, 2008; Sheen et al, 2007; Nakamura R et al, 2005; Burd et al, 1989; Kato et al, 2009; Price et al, 2009; Ršnnberg E et al, 2010; Kondo et al, 2008; Moulin D et al, 2007; Lappalainen J et al, 2011)
¥¥ CCL2 (CC chemokine ligand 2, chemokine (C-C motif) ligand 2, GDCF, Glioma-derived monocyte chemotactic factor-2, GDCF-2, HC11, JE, LDCF, MCAF, MCP, monocyte chemoattractant protein, MCP-1, monocyte chemoattractant protein-1, SMC-CF, smooth muscle cell chemotactic factor, TDCF, tumor-derived chemotactic factors, TSG-8, tumor necrosis factor-stimulated gene sequence-8, SCYA2) receptors (Taub et al, 1995)
¥ CCL3 (CC chemokine ligand 3, chemokine (C-C motif) ligand 3, MIP-1-alpha, macrophage inflammatory protein-1-alpha, 464.1, GOS-19-1, L2G25B, LD78, LD78-alpha, SCI, stem cell inhibition factor, stem cell inhibitor, TY5, SCYA3, SCYA3L1) (Gilchrest et al, 2003; Nakajima et al, 2002; King et al, 2002; Supajatura et al, 2002; Burd et al, 1989; Mortaz et al, 2008; Fischer et al, 2006; Kato et al, 2009; Kondo et al, 2008)
¥¥ CCL3 (CC chemokine ligand 3, chemokine (C-C motif) ligand 3, MIP-1-alpha, macrophage inflammatory protein-1-alpha, 464.1, GOS-19-1, L2G25B, LD78, LD78-alpha, SCI, stem cell inhibition factor, stem cell inhibitor, TY5, SCYA3, SCYA3L1) receptors (Taub et al, 1995)
¥ CCL4 (CC chemokine ligand 4, chemokine (C-C motif) ligand 4, SCYA4, ACT-2, Immune activation gene-2, 744.1, G26, H400, HC21, Cytokine 21, human, LAG-1, lymphocyte activation gene-1, MIP-1-beta, macrophage inflammatory protein-1-beta, SIS-gamma) (Nakajima et al, 2002; Selvan et al, 1994; King et al, 2002; Burd et al, 1989; Ali et al, 2000; Fischer et al, 2006; Kato et al, 2009; Kondo et al, 2008)
¥ CCL5 (CC chemokine ligand 5, chemokine (C-C motif) ligand 5, RANTES, EoCP-1, Eosinophil chemotactic polypeptide-1, SIS-delta, TCP228, T-cell-specific protein p228, SCYA5) (Kimura et al, 2002; King et al, 2002; Zhao et al, 2002; Selvan et al, 1994; Kempuraj et al, 2005; Kulka et al, 2008; Sheen et al, 2007; Brown et al, 2006; Bulanova et al, 2009; Ršnnberg E et al, 2010; Kondo et al, 2008)
¥¥ CCL5 (CC chemokine ligand 5, chemokine (C-C motif) ligand 5, RANTES, EoCP-1, Eosinophil chemotactic polypeptide-1, SIS-delta, TCP228, T-cell-specific protein p228, SCYA5) receptors (Taub et al, 1995; Zhao et al, 2002)
¥ CCL7 (CC chemokine ligand 7, chemokine (C-C motif) ligand 7, SCYA7, MCP-3, monocyte chemoattractant protein-3, FIC, Fibroblast-inducible cytokine, NC28, MARC, mast cell activation-related chemokine) (Kulmburg et al, 1992; Wakahara et al, 2001; Kato et al, 2009; Ršnnberg E et al, 2010)
¥ CCL11 (CC chemokine ligand 11, chemokine (C-C motif) ligand 11, SCYA11, Eotaxin, Eotaxin-1) (Kimura et al, 2002)
¥ CCL17 (CC chemokine ligand 17, chemokine (C-C motif) ligand 17, SCYA17, TARC, Thymus and Activation Regulated Chemokine, ABCD-2) (Oliveira and Lukacs, 2001; Wakahara et al, 2001; Ying S et al, 2008)
¥ CCL18 (CC chemokine ligand 18, chemokine (C-C motif) ligand 18, AMAC-1, alternative activated macrophage associated CC-Chemokine, PARC, pulmonary and activation-regulated chemokine, MIP-4, macrophage inflammatory protein-4, DC-CK1, dendritic cell-derived chemokine-1, Ck-beta-7, Met-chemokine-beta-7, Met-Ck-beta-7, SCYA18) (Kato et al, 2009)
¥ CCL20 (CC chemokine ligand 20, chemokine (C-C motif) ligand 20, SCYA20, LARC, Liver and Activation Regulated Chemokine, Exodus, Exodus-1, MIP-3-alpha, macrophage inflammatory protein-3-alpha, Ck-beta-4, Chemokine-beta-4, ST38) (Lin et al, 2003; Wakahara et al, 2001)
¥ CCL22 (CC chemokine ligand 22, chemokine (C-C motif) ligand 22, ABCD-1, DC/B-Ck, dendritic cell/B-cell derived chemokine, MDC, Human macrophage-derived chemokine STCP-1, stimulated T-cell chemotactic protein, SCYA22) (Oliveira and Lukacs, 2001; Wakahara et al, 2001)
¥ CCL27 (CC chemokine ligand 27, chemokine (C-C motif) ligand 27, ALP, CTACK, cutaneous T-cell attracting chemokine, ESkine, Embryonic stem cell chemokine, ILC, interleukin-11 receptor alpha-locus chemokine, IL11Ralpha-locus chemokine, PESKY, skinkine, SCYA27) (Tsuchiya S et al, 2009)
¥ CCR1 (CC-Chemokine receptor 1, RANTES receptor, MIP-1-alpha receptor, LD78 receptor, CC-CKR1, HM145, YT4, CD191, CMKBR1, chemokine-beta receptor 1) (Juremalm et al, 2002; Zhao et al, 2002; Oliveira and Lukacs, 2001; Amin et al, 2005)
¥ CCR2 (CC-Chemokine receptor 2, CC-CKR2A, CCR2A, CC-CKR2B, CCR2B, MCP-1 receptor A, MCP-1 receptor B, CMKBR2, chemokine-beta receptor 2, CD192) (Oliveira and Lukacs, 2001)
¥ CCR3 (CC-Chemokine receptor 3, CC-CKR3, Eotaxin receptor, CMKBR3, chemokine-beta receptor 3, MIP-1-alpha RL2, MIP-1-alpha receptor-like-2, CD193) (de Paulis et al, 2001; Oliveira and Lukacs, 2001; Ochi et al, 1999)
¥ CCR4 (CC-Chemokine receptor 4, CC-CKR4, CKR4, CMKBR4, chemokine-beta receptor 4, K5-5, CD194) (Juremalm et al, 2002; Zhao et al, 2002; Amin et al, 2005)
¥ CCR5 (CC-Chemokine receptor 5, CC-CKR5, CMKBR5, ChemR13, CD195) (Zhao et al, 2002; Oliveira and Lukacs, 2001; Ochi et al, 1999)
¥ CCR8 (CC-Chemokine receptor 8, TER1, CY6, ChemR1, CMKBR8, chemokine-beta receptor 8, CKR-L1 CDw198) (TCA-3) (Burd et al, 1989; Oh and Metcalfe, 1996)
(Schernthaner et al, 2001)
¥ CCRL2 (Chemokine CC Receptor-like-2, HCR, Human chemokine receptor, CCRL2A, Chemokine CC Receptor-like-2A, CCRL2B, Chemokine CC Receptor-like-2B, CRAM-A, chemokine receptor expressed in activated monocytes A, CRAM-B, chemokine receptor expressed in activated monocytes B, CRAM, chemokine receptor expressed in activated monocytes) (Zabel BA et al, 2008)
¥ CD2 (T11, 35.1, M-T910, 9.6, OX34, Tp50, LFA-2, lymphocyte function-associated antigen-2, Leu5, Leu5b, Ly37, OKT11, SRBC receptor, sheep red blood cell receptor, sheep erythrocyte receptor, erythrocyte receptor, E-rosette receptor, Rosette receptor, HuLy-m1) (Schernthaner et al, 2001)
¥ CD4 (T4, Leu3, OKT4, L3T4, Ly4, W3/25, OX38, OX35) (Soilleux et al, 2009)
¥ CD8-alpha (CD8a, Lyt2, Ly2, OX8) (Hara et al, 1994; Lin et al, 1998)
¥ CD9 (602-29 antigen, ALB6 antigen, BA2, BTCC-1, DRAP-27, Diphtheria toxin receptor associated protein 27 kDa, GIG2, MIC3, MRP-1, Motility-related protein-1, NCA, neural cell surface antigen, p24, SH-9, TSPAN29, tetraspanin 29) (Saito et al, 1995; Nilsson et al, 1993; Sperr et al, 1994; Kiener et al, 1998; Ghannadan et al, 1998; Valent et al, 1989)
¥ CD11a (ITGAL, integrin-alpha-L, LFA-1, Ly15, Ly21, LFA-1, lymphocyte function-associated antigen-1, LFA-1-alpha, lymphocyte function-associated antigen-1-alpha, neutrophil adherence receptor alpha-M subunit, OND(a), OND) (Toru et al, 1997)
¥ CD11b (CR3, CR3a, complement receptor-3, C3bi receptor, ITGAM, integrin-alpha-M, HNA4a, human neutrophil antigen 4a, MART, MART(a), Mo1, Ly40, Mac-1, OKM1, OX42, VIM12) (Welker et al, 2000)
¥ CD13 (alanyl aminopeptidase, AAP, ANPEP, alpha-aminoacyl-peptide hydrolase (microsomal), aminopeptidase N, PEPN, APN, APM, aminopeptidase M, EC3.4.11.2, LAP1, microsomal aminopeptidase, MY7, MCS-2, gp150) (Saito et al, 1995; Nilsson et al, 1993; Chirumbolo et al, 2008)
¥ CD14 (endotoxin receptor, Leu M3, LPS-R, Mo2, MY4, myeloid cell-specific leucine-rich glycoprotein, hdl, heedless) (Saito et al, 1995; Welker et al, 2000)
¥ CD16 (hFcRIII, Fc-gamma R3, FCGR3A, FCGR3, Neutrophil antigen NA, HNA1, human neutrophil antigen 1, Leu11, VEP13, B73.1, 31D8, N901) (Chong et al, 2003; Katz and Lobell, 1995; Latour et al, 1992)
¥ CD22 (CD22a, CD22-alpha, CD22b, CD22-beta, CD22c, CD22.1, CD22.2, HD6 antigen, HD39 antigen, BLCAM, B-lymphocyte cell adhesion molecule, Leu14, Lyb8, Lyb8.2, Lyb8a, SIGLEC-2, sialic acid binding immunoglobulin-like lectin 2) (Yokoi et al, 2006)
¥ CD24 (CD24a, 30F1, B2A2, BA-1, HB8, VIB E3, HIS50, HSA, heat stable antigen, J11d, JIId, Ly52, M1/69, Nectadrin, LR-1, SCLC surface antigen Cluster-4, CL-4; R13-Ag, R13 antigen, X62 heat stable antigen) (Tsuchiya S et al, 2009)
¥ CD28 (T90/44, Tp44, Kolt-2) (Tashiro et al, 1997)
¥ CD29 (FNRB, fibronectin receptor beta chain, ITGB1, integrin-beta-1, platelet protein GPIIa, VLA-beta, very late activation antigen-beta, VLA-beta-1, VLA-4 beta subunit) (Saito et al, 1995; Sperr et al, 1992; Nilsson et al, 1993; Ducharme and Weis, 1992; Lorentz et al, 2002; Shimizu et al, 2002; Kiener et al, 1998; Ghannadan et al, 1998; Tsuchiya S et al, 2009; Krauth et al, 2005)
¥ CD30 ligand (CD30L, CD153, TNFSF8, TNF ligand superfamily member 8) (Fischer et al, 2003, 2006; Carvalho et al, 2009; Nakae et al, 2006)
¥ CD32 (hFcRII, Fc-gamma R2, FCG2, FCGR2, CD32a, CD32b, FCGR2A, Fc-gamma R2a, FCGR2B, Fc-gamma R2b, IGFR2, immunoglobulin G Fc receptor 2) (Ghannadan et al, 1998)
¥ CD33 (CD33M, CD33m, MY9, SIGLEC-3, sialic acid binding immunoglobulin-like lectin 3) (Saito et al, 1995; Nilsson et al, 1993; Welker et al, 2000; Kiener et al, 1998; Yokoi et al, 2006; Ghannadan et al, 1998; Valent et al, 1989; Krauth et al, 2005)
¥ CD34 (hemopoietic progenitor cell antigen 1, HPCA1, gp105-120, BI.3C5, ICH3, MY10, 188.27) (Drew et al, 2002, 2005, 2005)
¥ CD35 (C3 binding protein, C3b receptor, C3bR, C3b/C4b receptor, C4b receptor, complement 3b/4b receptor, CR1, complement receptor-1, Knops blood group antigen, Kn(a), Kn(b), McCoy blood group antigen, McC, Swain-Langley blood group antigen, Sl, Yk(a), York blood group antigen) (Schernthaner et al, 2005)
¥ CD38 (ADP-ribosyl cyclase, ADP-ribosyl cyclase-1, cyclic ADP-ribose hydrolase, ecto-NAD+ glycohydrolase, Ecto-nicotinamide adenine dinucleotide glycohydrolase, EC3.2.2.5, Leu17, OKT10, T10) (Saito et al, 1995)
¥ CD40 ligand (CD40L, CD40LG, TRAP, TNF-related activation protein, CD154, 5c8, gp39, Ly62, T-BAM, IMD3, TNFSF5, TNF ligand superfamily member 5) (Pawankar et al, 1997; Gauchat et al, 1993)
¥ CD41b CD41, Bak, Bak(a), Bak(b), GPIIb, platelet glycoprotein IIb, HPA-3, human platelet antigen-3, ITGAB, integrin-alpha-2b, Lek(a)) (Lorentz et al, 2002)
¥ CD43 (3E8 antigen, GALGP, galactoglycoprotein, gpL115, L60, Leu22, Lp-3, LSN, leukosialin, Ly48, MT1, OX75, S7 antigen, SPN, sialophorin, W3/13) (Saito et al, 1995; Nilsson et al, 1993; Kiener et al, 1998; Valent et al, 1990; Ghannadan et al, 1998)
¥ CD44 (CDw44, CD44H, CD44A, CD44s, CD44st, CD44std, AnWj blood group antigen, ECMR-3, extracellular matrix receptor-3, class 3 ECMR, gp85, HCAM, homing-associated cell adhesion molecule, Hermes-1, Hermes antigen, HUTCH-1, Indian blood group antigen, In blood group antigen, Ly24, MC56, MDU2, MDU3, MIC4, MUC 2-63, OX49, PGP1, PGP1.1, phagocytic glycoprotein-1, GM35 antigen) (Saito et al, 1995; Sperr et al, 1994; Kiener et al, 1998; Valent et al, 1990; Bulfone-Paus and Paus, 2008; Ghannadan et al, 1998; Krauth et al, 2005)
¥ CD45 (B220, HuLy-m4, LCA, leukocyte common antigen, Ly5, OX1, OX22, OX30, PTPRC, protein tyrosine phosphatase receptor type C, EC3.1.3.4, T200) (Saito et al, 1995; Nilsson et al, 1993; Sperr et al, 1994; Kiener et al, 1998; Virts et al, 1997; Ghannadan et al, 1998; Valent et al, 1989; Krauth et al, 2005; Chirumbolo et al, 2008)
¥ CD46 (gp45-70, HuLy-m5, MCP, membrane cofactor protein, measles virus receptor, MIC10, TLX, TRA-2-10, trophoblast-leukocyte common antigen, trophoblast-lymphocyte cross-reactive antigen) (Saito et al, 1995; Fureder et al, 1995; Ghannadan et al, 1998)
¥ CD47 (1D8, B6H12, BRIC 126, IAP, integrin-associated protein, integrin-associated signal transducer, MER6, OA3, ovarian carcinoma antigen 3, OVTL3) (Saito et al, 1995; Krauth et al, 2005; Ghannadan et al, 1998)
¥ CD47R (CDw149, CD149, gp42, MEM-133, neurophilin, OA3, Rh-associated protein) (Ghannadan et al, 1998)
¥ CD48 (17D6, 5-8A10, 6.28, BCM1, B-cell activation marker 1, BLAST, B-LAST 1, Blast-1, HM48-1, Ly-m3, HuLy-m3, MEM-102, OX45, OX46, OX78, sgp-60, SLAMF2, signaling lymphocyte activation molecule family member 2, SLAM family member 2, TCT.1, T-cell target 1) (Saito et al, 1995; Malaviya et al, 1999; Ghannadan et al, 1998)
¥ CD49b (Br alloantigen, DX5, ECMR-2, extracellular matrix receptor-2, GPIa, HPA-5, human platelet antigen-5, ITGA2, integrin-alpha-2, platelet glycoprotein Ia/IIa, VLA-2, very late activation antigen 2, VLAA2, VLA2 receptor alpha 2 subunit, Zav alloantigen) (Schoeler et al, 2003; Lorentz et al, 2002)
¥ CD49c (CSAT antigen band 2 protein, FRP-2, fusion regulatory protein-2, GAP-B3, galactoprotein B3, ITGA3, integrin-alpha-3, MSK18, VLA-3, very late activation antigen 3, ECMR-1, Extracellular matrix receptor-1, class 1 ECMR, VLA-alpha 3, very late activation antigen alpha-3, VLAA3, VLA-3 receptor alpha 3 subunit) (Wimazal et al, 1999; Tsuchiya S et al, 2009)
¥ CD49d (ITGA4, integrin-alpha-4, VLA-4, very late activation antigen 4, VLAA4, VLA4 receptor alpha 4 subunit, VLA-alpha 4, very late activation antigen alpha-4) (Saito et al, 1995; Sperr et al, 1992; Ducharme and Weis, 1992; Lorentz et al, 2002; Shimizu et al, 2002; Ghannadan et al, 1998)
¥ CD49e (fibronectin receptor alpha chain, FNRA, ITGA5, integrin-alpha-5, ECMR-6, Extracellular matrix receptor-6, class 6 ECMR, GPIc, platelet glycoprotein Ic, VLA-alpha 5, very late activation antigen alpha-5, VLA-5, very late activation antigen 5, VLA-5-alpha) (Sperr et al, 1992; Schoeler et al, 2003)
¥ CD49f (ITGA6, integrin-alpha-6, platelet gpI, VLA-6, very late activation antigen 6, VLA-6 alpha chain, VLA-alpha 6, very late activation antigen alpha-6, GPIc*, platelet glycoprotein Ic*) (Schoeler et al, 2003)
¥ CD50 (ICAM-3, intercellular adhesion molecule 3, ICAM-R, ICAM receptor) (Saito et al, 1995; Babina et al, 1999; Ghannadan et al, 1998; Babina et al, 2001)
¥ CD51 (ITGAV, integrin-alpha-V, L230, MSK8 vitronectin receptor VNRA, vitronectin receptor alpha subunit) (Saito et al, 1995; Sperr et al, 1992; Bianchine et al, 1992; Shimizu et al, 1995; Schoeler et al, 2003; Lorentz et al, 2002; Shimizu et al, 2002; Yokoi et al, 2006; Ghannadan et al, 1998)
¥ CD53 (MRC OX44, MOX44, TSPAN25, tetraspanin 25) (Saito et al, 1995; Ghannadan et al, 1998)
¥ CD54 (7F7, BB2, human rhinovirus receptor, ICAM-1, intercellular adhesion molecule 1, IFN-gamma regulated human melanoma-associated antigen, Ly47, MALA-2, Me14-D12, P3.58) (Saito et al, 1995; Sperr et al, 1994; Wedi et al, 1996; Valent et al, 1991; Shimizu et al, 2002; Ghannadan et al, 1998; Stahl et al, 1999; Toru et al, 1997; Okumura et al, 2009; Krauth et al, 2005)
¥ CD55 (CD55a, CD55b, complement decay-accelerating factor, decay-accelerating factor, DAF, DAF-GPI, DAF-TM, GPI-DAF, TM-DAF, DAF1, decay-accelerating factor 1, DAF2, decay-accelerating factor 2, Cromer blood group antigen) (Saito et al, 1995; Fureder et al, 1995; Ghannadan et al, 1998; Krauth et al, 2005; Tsuchiya S et al, 2009)
¥ CD56 (5.1.H11, BASCA, brain-associated small cell lung cancer antigen, Leu19, MSK39, NCAM, neural cell adhesion molecule, NCAM1, neural cell adhesion molecule-1, NCAM-120, neural cell adhesion molecule-120, NCAM-140, neural cell adhesion molecule-140, NCAM-180, neural cell adhesion molecule-180, NKH-1, PSA-NCAM, polysialylated NCAM, E-NCAM, embryonic NCAM, embryonic neural cell adhesion molecule) (Tsuchiya S et al, 2009)
¥ CD58 (LFA-3, lymphocyte function-associated antigen-3, T11TS, T11 target structure) (Saito et al, 1995; Ghannadan et al, 1998; Schernthaner et al, 2001; Krauth et al, 2005)
¥ CD59 (CD59a, protectin, MIC11, MIN2, MIN3, MSK21, HRF20, homologous restriction factor-20 kDa, MACIF, membrane attack complex inhibitory factor, MAC-IP, MAC-inhibitory protein, H19, MIRL, membrane inhibitor of reactive lysis, P18, 1F5, 16.3A5, BRIC 229, YTH 53.1) (Saito et al, 1995; Fureder et al, 1995; Ghannadan et al, 1998)
¥ CD60 (CDw60, CD60a, GD3) (Saito et al, 1995; Ghannadan et al, 1998)
¥ CD61 (CD61A, F4, F11, GPIIb/IIIa, HPA-1, human platelet antigen-1, HPA-4, human platelet antigen-4, ITGB3, integrin-beta-3, Pen alloantigen, Pen(a), Pen(b), PL(A1), platelet fibrinogen receptor beta subunit, platelet glycoprotein IIIa, GP3A, Yuk alloantigen, Yuk(a), Yuk(b), Zw alloantigen, Zw(a), Zw(b)) (Saito et al, 1995; Sperr et al, 1992; Shimizu et al, 1995; Shimizu et al, 2002; Ghannadan et al, 1998)
¥ CD63 (81H, AD1, GP55, granulophysin, HOP-26, LIMP, lysosomal integral membrane protein, LIMP-1, lysosomal integral membrane protein-1, ME491, melanoma associated antigen ME491, MLA1, melanoma-associated antigen 1, NGA, neuroglandular antigen, NKI-C3, OMA81H, ocular melanoma-associated antigen 81H, PLTGP40, platelet glycoprotein gp40, TSPAN30, tetraspanin 30) (Nishikata et al, 1992; Ghannadan et al, 1998; Tsuchiya S et al, 2009; Krauth et al, 2005; Chirumbolo et al, 2008)
¥ CD64 (hFcRI, FCGR1, Fc-gamma R1, FCGR1A, Fc-gamma R1A, FCGR1B, Fc-gamma R1B, FCGR1C, Fc-gamma R1C) (Welker et al, 2000; Okayama et al, 2003)
¥ CD68 (EBM11, gp110, Ki-M6, Ki-M7, KP-1, macrosialin, microsialin, PG-M1, PM-1k, SCARD1, scavenger receptor class D member 1, Y1/82A, Y2/131) (Welker et al, 2000)
¥ CD69 (AIM, activation inducer molecule, BL-AC/P26, CLEC2C, C-type lectin domain family 2 member C, EA1, early antigen 1, early T-cell activation antigen p60, gp34/28, Leu23, MLR3, VEA) (Chirumbolo et al, 2008)
¥ CD72 (CD72a, CD72b, CD72c, Lyb2, Ly19, Ly19.2, Ly32, Ly32.2) (Kataoka et al, 2010)
¥ CD81 (2F7, 5A6, S5.7, TAPA-1, target of antiproliferative antibody 1, TSPAN28, tetraspanin 28) (Ghannadan et al, 1998)
¥ CD82 (4F9, C33, GR15, IA4, KAI1, KANGAI-1, R2, Inducible membrane protein R2, SAR2, surface antigen R2, ST6, suppressor of tumorigenicity-6, TSPAN27, tetraspanin 27) (Ghannadan et al, 1998)
¥ CD84 (CDw84, Ly9b, lymphocyte antigen 9b, lymphocyte antigen 9-beta, Ly9-beta, MAX.3 antigen, SLAMF5, signaling lymphocyte activation molecule family member 5, SLAM family member 5) (Ghannadan et al, 1998; Tsuchiya S et al, 2009; çlvarez-Errico et al, 2011)
¥ CD85c (LILRB5, leukocyte immunoglobulin-like receptor subfamily B member 5, LIR8, leukocyte immunoglobulin-like receptor 8) (Tedla et al, 2008)
¥ CD85k (LILRB4, leukocyte immunoglobulin-like receptor subfamily B member 4, ILT3, immunoglobulin-like transcript 3, LIR5, leukocyte immunoglobulin-like receptor 5, HM18, Monocyte inhibitory receptor HM18, gp49B, gp49B1, gp49B2) (Arm et al, 1997; Feldweg et al, 2003)
¥ CD86 (B70, B72, B7-2, BU-63, CD28 ligand-2, CD28LG2, CLS1, FUN-1, GR65, LAB7-2, Ly58, MB7) (Valent et al, 1989)
¥ CD87 (MO3, PLAUR, plasminogen activator urokinase receptor, UPA-R, urokinase plasminogen activator receptor, URKR, urokinase receptor) (Ghannadan et al, 1998; Bankl et al, 2001)
¥ CD88 (C5aR, C5a receptor, C5R1, complement component 5 receptor 1) (Andersson et al, 2010; Baumann et al, 2001; Ghannadan et al, 1998; Hartmann et al, 1997; Kiener et al, 1998; Langkabel et al, 1999; Mullaly SC and Kubes P, 2007; Oksjoki et al, 2007; Oskeritzian et al, 2005; Price et al, 2009; Schernthaner et al, 2005; Soruri et al, 2008; Thangam et al, 2005; Werfel et al, 1997; Wojta et al, 2002)
¥ CD90 (5E10, OX7, Thy1 [thymus cell antigen 1, Thy1.1, Thy1.2) (Tsuchiya S et al, 2009)
¥ CD92 (CTL1, CHTL1, choline transporter-like protein 1, GR9, SLC44A1 [solute carrier family 44 member 1) (Ghannadan et al, 1998)
¥ CD95 (FAS, APO-1, apoptosis antigen-1, APT1, TNFRSF6, TNF receptor superfamily member 6, FASTM, FASL receptor) (Nakae et al, 2006)
¥ CD97 (BL-KDD/F12, GR1, TM7LN1, AURA51, augmented in rheumatoid arthritis 51) (Ghannadan et al, 1998)
¥ CD98 (CD98LC, 4F2lc, 4F2, 4F2hc, FRP-1, fusion regulatory protein-1, LAT1, system-L amino acid transporter 1, L-type amino acid transporter 1, Ly10, Ly-m10, MDU1, MPE16, membrane protein E16, RL-388, SLC3A2, solute carrier family 3 member 2, SLC7A5, solute carrier family 7 member 5) (Ghannadan et al, 1998; Tsuchiya S et al, 2009)
¥ CD99 (12E7, MIC2, MIC2X, MIC2Y, E2 antigen, CD99R, O13, hec2, HBA-71) (Ghannadan et al, 1998)
¥ CD103 (a6, HML1, human mucosal lymphocyte antigen 1, ITGAE, integrin-alpha-E, OX62) (Wright et al, 2002)
¥ CD105 (endoglin, ENG, Edg, L-endoglin, S-endoglin, E9 protein, MJ7/18 antigen, HHT1, hereditary hemorrhagic telangiectasia type 1, ORW, Osler-Rendu-Weber syndrome, ORW1, SH-2) (Tsuchiya S et al, 2009; Zhao W et al, 2008)
¥ CD106 (alpha-4-beta-1 ligand, INCAM-110, inducible cellular adhesion molecule 110 kDa, VCAM-1, vascular cellular adhesion molecule 1) (Tsuchiya S et al, 2009; Okumura et al, 2009)
¥ CD144 (7B4, cadherin-5, CDH5, VEC, vascular-endothelial cadherin, VE-cadherin, vascular-endothelial cadherin) (Tsuchiya S et al, 2009)
¥ CD151 (PETA-3, platelet-endothelial cell tetraspan antigen 3, SFA-1, SF-HT activated gene 1, TSPAN24, tetraspanin 24, RAPH, Raph blood group) (Wimazal et al, 1999; Ghannadan et al, 1998; Tsuchiya S et al, 2009)
¥ CD143 (ACE, angiotensin converting enzyme, angiotensin-1 converting enzyme, dipeptidyl carboxypeptidase,

dipeptidyl carboxypeptidase 1, EC3.4.15.1, kininase 2, peptidase P, peptidyl dipeptidase A) (Tsuchiya S et al, 2009)
¥ CD146 (A32, BT14, L101, gp130 antigen, MCAM, Melanoma cell adhesion molecule, MelCAM, melanoma adhesion molecule, MUC18, P1H12, S-endo 1, Gicerin, 1-gicerin, s-gicerin) (Tsuchiya S et al, 2009)
¥ CD151 (PETA-3, platelet-endothelial cell tetraspan antigen 3, SFA-1, SF-HT activated gene 1, TSPAN24, tetraspanin 24, RAPH, Raph blood group) (Krauth et al, 2005)
¥ CD157 (BST-1, bone marrow stromal cell antigen-1, Bsta1, 114/A10, ADP-ribosyl cyclase-2, BP-3, BP-3/IF-7, Cyclic ADP-ribose hydrolase 2, EC3.2.2.5, Ly65, MO-5) (Wimazal et al, 1999; Ghannadan et al, 1998)
¥ CD160 (BY55, NK1, NK28) (Ortonne et al, 2011)
¥ CD166 (2117 antigen, ALCAM, Activated leukocyte cell adhesion molecule, BEN, CD6L-100, DM-GRASP, F84.1 antigen, HCA, Hematopoietic cell antigen, JC7, KG-CAM, MEMD, melanoma metastasizing clone D, metastasizing melanoma protein D, MuSC, Neurolin, SC-1) (Tsuchiya S et al, 2009)
¥ CD172A (BIT, brain Ig-like molecule with tyrosine-based activation motif, MFR, macrophage fusion receptor, MYD1, p84, PTPNS1, protein tyrosine phosphatase nonreceptor type substrate 1, OX41, SHPS1, SHP substrate 1, SIRP-alpha, SIRP-alpha-1, signal regulatory protein-alpha, tyrosine phosphatase SHP substrate 1) (Ghannadan et al, 2002; Krauth et al, 2005)
¥ CD200R (CD200R1 CD200 receptor, CD200 receptor 1, OX2 receptor, OX2R, MOX2 receptor, MOX2R) (Cherwinski et al, 2005; Kojima et al, 2007; Zhang et al, 2004)
¥ CD201 (APC receptor, Activated protein C receptor, CCCA, cell cycle centrosome associated protein, CCD41, EPC-R, endothelial protein C receptor, PROCR, protein C receptor) (Ghannadan et al, 2002)
¥ CD203c (97A6 antigen, B10, bovine intestinal phosphodiesterase, ENPP-1, ectonucleotide pyrophosphatase/phosphatase 1, gp130RB13-6, Ly41, M6S1, membrane component chromosome 6 surface marker-1, NPP-3, nucleotide pyrophosphatase/phosphodiesterase 3, Pca-1, PD-1-beta, phosphodiesterase-1-beta, PDNP3, phosphodiesterase/nucleotide pyrophosphatase 3, tiptoe walking, ttw) (Ghannadan et al, 2002; Hauswirth et al, 2008; Chirumbolo et al, 2008; Krauth et al, 2005)
¥ CD244 (2B4, 2B4-S, 2B4-L, C1.7, C9.1, Ly90, NAIL, NK-cell activation-inducing ligand, NKR2B4, natural killer cell receptor 2B4, NK-cell receptor 2B4, Nmrk, Non-MHC restricted killing associated, p38, SLAMF4, signaling lymphocyte activation molecule family member 4) (Kubota et al, 2002)
¥ CD252 (CD134 ligand, CD134L, gp34, OX40 ligand, OX40L, TNFSF4, TNF ligand superfamily member 4, TXGP1, tax-transcriptionally activated glycoprotein 1) (Nakano et al, 2009; Nakae et al, 2006)
¥ CD275 (B7-H2, B7RP-1, B7-related protein 1, GL50, H4, ICOSL, inducible T-cell co-stimulator ligand, ICOS ligand, KIAA0653, LICOS, ligand for ICOS) (Nakae et al, 2006; Florian S et al, 2006)
¥ CD300A (CMRF35H, CMRF35H9, IGSF12, immunoglobulin superfamily member 12, IRC1, IRC2, IRp60, Inhibitory receptor protein 60, MAIR-I, myeloid-associated immunoglobulin-like receptor I, CLM8, CMRF35-like molecule-8, LMIR1, leukocyte mono-Ig-like receptor 1) (Bachelet et al, 2005; Yotsumoto et al, 2003)
¥ CD300B (CD300LB, CD300 molecule-like family member B, CLM7, CMRF35-like molecule-7, CMRF35-like molecule-7, IREM3, immune receptor expressed by myeloid cells 3, TREM5, triggering receptor expressed on myeloid cells 5, MAIR-VII, myeloid-associated immunoglobulin-like receptor VII, LMIR5, leukocyte mono-Ig-like receptor 5) (Yamanishi et al, 2008)
¥
CD300D (CD300LD; MAIR-II, myeloid-associated immunoglobulin-like receptor II, CLM4, CMRF35-like molecule-4, LMIR2, leukocyte mono-Ig-like receptor 2, DIgR1, DC-derived Ig-like receptor 1; Dendritic cell-derived Ig-like receptor 1, CMRF35A4, CMRF35-like molecule A4) (Kumagai et al, 2003)
¥ CD300F (CD300LF, CD300 molecule-like family member F, CLM1, CMRF35-like molecule-1, IGSF13, immunoglobulin superfamily member 13, IREM1, immune receptor expressed on myeloid cells 1, NKIR, NK inhibitory receptor, MAIR-V, myeloid-associated immunoglobulin-like receptor V, LMIR3, leukocyte mono-Ig-like receptor 3, CLM1, CMRF35-like molecule-1, DIgR2, DC-derived Ig-like receptor 2; Dendritic cell-derived Ig-like receptor 2) (Izawa et al, 2007)
¥ CD305 (LAIR1, leukocyte-associated Ig-like receptor 1, 9.1C3) (Florian S et al, 2006)
¥ CD312 (EMR2, EGF-like module containing mucin-like hormone receptor-like-2) (Florian S et al, 2006)
¥ CD317 (120G8 antigen, BST-2, bone marrow stromal cell antigen-2, PDCA-1, plasmacytoid dendritic cell antigen-1, Tetherin, HM1.24 antigen) (Blasius et al, 2006)
¥ Chemerin (RARRES2, retinoic acid receptor responder 2, tazarotene-induced gene-2, TIG2) (Albanesi et al, 2009)
¥¥ Chemerin (RARRES2, retinoic acid receptor responder 2, tazarotene-induced gene-2, TIG2) receptors (ChemerinR, ChemR23, chemokine receptor 23, CMKLR1, chemokine-like receptor 1, Dez) (Zabel BA et al, 2008)
¥¥ cholecystokinin (CCK, pancreozymin) receptors (Juanola et al, 1998)
¥ chromogranin A (CGA, CHGA, granin A, Parathyroid secretory protein-1, Parathyroid secretory protein, PSP, PSP1, pituitary secretory protein-1, Secretory protein-1, SG-I, catestatin) (Tsuchiya S et al, 2009; Aung et al, 2011)
¥¥ chromogranin A (CGA, CHGA, granin A, Parathyroid secretory protein-1, Parathyroid secretory protein, PSP, PSP1, pituitary secretory protein-1, Secretory protein-1, SG-I, catestatin) receptors (Aung et al, 2011)
¥ CIDE-A (Cell death-inducing DFF45-like effector A) (Lora et al, 2003)
¥ CISH (Cytokine inducible SH2-containing protein, CIS, Cytokine inducible SH2-containing protein, CIS1, G18, SOCS, Suppressor of cytokine signaling) (Nakamura R et al, 2005)
¥ CKLFSF8 (chemokine-like factor superfamily member 8, CMTM8, CKLF-like MARVEL transmembrane domain-containing protein 8) (Tsuchiya S et al, 2009)
¥ CLM5 (CMRF35-like molecule-5, MAIR-IV, myeloid-associated immunoglobulin-like receptor IV; LMIR4; leukocyte mono-Ig-like receptor 4) (Enomoto et al, 2010; Izawa et al, 2007)
¥ Clusterin (CLU, dimeric acidic glycoprotein, DAG protein, testosterone repressed prostate message-2, TRPM-2, sulfated glycoprotein-2, SGP-2, complement-associated protein SP-40,40, SP-40,40, complement lysis inhibitor, CLI, Apolipoprotein J) (Tsuchiya S et al, 2009)
¥ collagen type 4 (COL4A1, collagen-4-alpha-1, collagen-4, Arresten, Canstatin, Tumstatin) (Thompson et al, 1991)
¥¥ Corticotropin releasing hormone (CRH, CRF, Corticotropin releasing factor, Corticoliberin) receptors (McEvoy et al, 2001; Cao et al, 2006; Theoharides et al, 2009)
¥¥ CRLF-3 (cytokine receptor-like factor-3, CREME-9, Cytokine receptor-like molecule 9, Cytokine receptor-related protein 4, type I cytokine receptor-like factor p48, CYTOR4) (Tsuchiya S et al, 2009)
¥ crystallin alpha C (Cryac) (Tsuchiya S et al, 2009)
¥ CTRP1 (C1q/TNF-related protein 1, C1QTNF1, Complement C1q tumor necrosis factor-related protein 1, C1q and tumor necrosis factor related protein 1, GIP, G protein-coupled receptor-interacting protein, ZSIG37) (Tsuchiya S et al, 2009)
¥ CX3CL1 (fractalkine, FKN, FK, CX3C membrane-anchored chemokine, C3Xkine, neurotactin, NTT, NTN, ABCD-3, SCYD1) (Tsuchiya S et al, 2009)
¥¥ CX3CL1 (fractalkine, FKN, FK, CX3C membrane-anchored chemokine, C3Xkine, neurotactin, NTT, NTN, ABCD-3, SCYD1) receptors (CX3CR1, V28, CMKBRL1, chemokine beta receptor-like-1, GPR13, G-protein-coupled receptor-13) (Papadopoulos et al, 2000; El-Shazly et al, 2006)
¥ CXCL1 (CXC chemokine ligand 1, chemokine (C-X-C motif) ligand 1, SCYB1, CINC-1, Cytokine induced neutrophil chemoattractant-1, fsp, fibroblast secretory protein, GRO1, GRO-alpha, KC, MGSA, melanoma growth stimulatory activity, MGSA-alpha, melanoma growth stimulatory activity-alpha, NAP-3, neutrophil-activating protein-3, N51) (Biedermann et al, 2000; Williams and Coleman, 1995; Ajuebor et al, 1999; Bulanova et al, 2009; Ramos et al, 2003; Olivera et al, 2002)
¥ CXCL2 (CXC chemokine ligand 2, chemokine (C-X-C motif) ligand 2, CINC-2-alpha, Cytokine induced neutrophil chemoattractant-2-alpha, GRO2, growth-related oncogene-2, GRO-beta, growth regulated oncogene-beta, MIP-2-alpha, macrophage inflammatory protein-2-alpha, MGSA-beta, melanoma growth stimulatory activity-beta, SCYB2) (Mortaz et al, 2008; Ršnnberg E et al, 2010)
¥ CXCL3 (CXC chemokine ligand 3, chemokine (C-X-C motif) ligand 3, CINC-2-beta, Cytokine induced neutrophil chemoattractant-2-beta, DCIP-1, DC inflammatory protein-1, GRO3, GRO-gamma, growth regulated oncogene-gamma, growth-related oncogene-3, MGSA-gamma, melanoma growth stimulatory activity-gamma, MIP-2-beta, macrophage inflammatory protein-2-beta) (Kato et al, 2009)
¥ CXCL4 (CXC chemokine ligand 4, chemokine (C-X-C motif) ligand 4, PF4, platelet factor-4, Endothelial cell growth inhibitor, Heparin neutralizing protein, Megakaryocyte-stimulatory-factor, Oncostatin A, SCYB4) (Tsuchiya et al, 2009)
¥¥ CXCL4 (CXC chemokine ligand 4, chemokine (C-X-C motif) ligand 4, PF4, platelet factor-4, Endothelial cell growth inhibitor, Heparin neutralizing protein, Megakaryocyte-stimulatory-factor, Oncostatin A, SCYB4) receptors (Suzuki et al, 2002; Taub et al, 1995)
¥ CXCL5 (CXC chemokine ligand 5, chemokine (C-X-C motif) ligand 5, ENA-78, Epithelial neutrophil-activating protein 78, epithelial cell-derived neutrophil attractant-78, LIX, LPS induced CXC chemokine, AMCF-2, Alveolar macrophage chemotactic factor-2, SCYB5) (Lukacs et al, 1998)
¥ CXCL9 (CXC chemokine ligand 9, chemokine (C-X-C motif) ligand 9, mig, monokine induced by gamma-Interferon, Humig, Mumig, CRG-10, cytokine responsive gene-10, M119, SCYB9) (Kulka et al, 2008)
¥ CXCL10 (CXC chemokine ligand 10, chemokine (C-X-C motif) ligand 10, IP-10, INP-10, inflammatory protein 10, Interferon-inducible protein-10, IFN-inducible protein 10, immune protein-10; 10 kDa interferon-inducible protein, gamma-IP-10, CRG-2, cytokine responsive gene-2, C7, Ifi10, interferon-inducible-10, mob-1, SCYB10) (Okumura et al, 2009; Ying S et al, 2008)
¥ CXCL12 (CXC chemokine ligand 12, chemokine (C-X-C motif) ligand 12, IRH, intercrine reduced in hepatomas, hIRH, intercrine reduced in hepatomas, SDF-1-alpha, CXCL12-alpha, SDF-1-beta, CXCL12-beta, SDF, SDF-1, Stromal cell-derived factor, Stromal cell-derived factor-1-alpha, Stromal cell-derived factor-1-beta, PBSF, pre-B-cell growth stimulating factor, TLSF, Thymic lymphoma cell stimulating factor, Thymic lymphoma cell stimulating factor-alpha, Thymic lymphoma cell stimulating factor-beta, TLSF-alpha, TLSF-beta, TPAR-1, TPA repressed gene-1, SCYB12) (Tsuchiya S et al, 2009)
¥¥ CXCL12 (CXC chemokine ligand 12, chemokine (C-X-C motif) ligand 12, IRH, intercrine reduced in hepatomas, hIRH, intercrine reduced in hepatomas, SDF-1-alpha, CXCL12-alpha, SDF-1-beta, CXCL12-beta, SDF, SDF-1, Stromal cell-derived factor, Stromal cell-derived factor-1-alpha, Stromal cell-derived factor-1-beta, PBSF, pre-B-cell growth stimulating factor, TLSF, Thymic lymphoma cell stimulating factor, Thymic lymphoma cell stimulating factor-alpha, Thymic lymphoma cell stimulating factor-beta, TLSF-alpha, TLSF-beta, TPAR-1, TPA repressed gene-1, SCYB12) receptors (Matsuura J et al, 2010)
¥ CXCR4 (CXC-Chemokine receptor 4, LESTR, leukocyte-derived 7-transmembrane domain receptor, HUMSTR, NPYRL, neuropeptide Y receptor-like, NPY3R, neuropeptide Y receptor Y3, HM89, Fusin, LCR-1, FB22, LAP3, Lipopolysaccharide-associated protein 3, SDF-1 receptor, CD184, AURA86, augmented in rheumatoid arthritis 86) (Lin et al, 2000; Juremalm et al, 2000; Ochi et al, 1999; Matsuura J et al, 2010)
¥ CXCR5 (MDR15, monocyte-derived receptor 15, blr-1, Burkitt lymphoma receptor-1, CD185) (Matsuura J et al, 2010)
¥ cystatin B (Tsuchiya S et al, 2009)
¥ Cystatin C (CST3, Cystatin-3, Gamma-TRACE, post-gamma globulin) (Tsuchiya S et al, 2009)

¥ D6 (CCBP2, chemokine binding protein-2, CMKBR9, chemokine-beta receptor 9) (McKimmie CS and Graham GJ, 2006; McKimmie CS et al, 2008)
¥ Dectin-1 (DC-associated C-type lectin 1, Dendritic cell-associated C-type lectin 1, dectin-1A, dectin-1B, CLEC7A, C-type lectin domain family 7 member A, CLECSF12, C-type lectin domain superfamily member 12, BGR, beta-glucan receptor, BGRA, Beta-glucan receptor A, BGRB, Beta-glucan receptor B) (Olynych et al, 2006; Ribbing et al, 2011; Yang and Marshall, 2009)
¥¥ defensin-alpha-1 (Defensin-1, Alpha-Defensin-1, HNP-1, human neutrophil peptide-1, HP-1, DEFA1, MRS, myeloid-related sequence, Cryptdin-1, defensin-related cryptdin peptide, Defcr, defensin-related cryptdin peptide-1, Defcr1, AURA28, augmented in rheumatoid arthritis 28) receptors (Befus et al, 1999; Grigat J et al, 2007)
¥¥ defensin-alpha-3 (Alpha-Defensin-3, defensin-alpha-3, DEFA3, DEF3, HNP-3, human neutrophil peptide-3, HP-3) receptors (Grigat J et al, 2007)
¥¥ defensin-alpha-4 (Alpha-Defensin-4, corticostatin HP-4, DEF4, DEFA4, HNP-4, human neutrophil peptide-4, HP-4, human neutrophil granule peptide-4) receptors (Befus et al, 1999)
¥¥ defensin-alpha-5 (HD-5, defensin-5, alpha-Defensin-5) receptors (Grigat J et al, 2007)
¥¥ defensin-beta-1 (beta-Defensin-1, HBD-1, DEFB1, DEFB101) receptors (Soruri et al, 2007)
¥¥ defensin-beta-2 (beta-Defensin-2, DEFB4, HBD-2, SAP-1, skin antimicrobial peptide 1) receptors (Niyonsaba et al, 2002, 2010; Soruri et al, 2007; Kase et al, 2009)
¥¥ defensin-beta-3 (beta-Defensin-3, HBD-3, DEFB103) receptors (Niyonsaba et al, 2010; Chen X et al, 2007; Soruri et al, 2007; Kanda et al, 2010)
¥ defensin-beta-4 (beta-Defensin-4, DEFB104, HBD-4) (Di Nardo et al, 2003)
¥¥ defensin-beta-4 (beta-Defensin-4, DEFB104, HBD-4) receptors (Niyonsaba et al, 2010; Chen X et al, 2007; Soruri et al, 2007)
¥ dickkopf-3 (dickkopf-related protein 3, dkk-3, REIC, reduced expression in cancer) (Tsuchiya S et al, 2009)
¥ Disialoganglioside GD3 (Ren et al, 2001)
¥ DR6 (death receptor-6, TNFRSF21, TNF receptor superfamily member 21, CD358) (Tsuchiya S et al, 2009)

¥ endothelin-1 (ET-1(1-21), ET-1, EDN1) (Coulombe et al, 2002; Ehrenreich et al, 1992)
¥¥ endothelin-1 (ET-1(1-21), ET-1, EDN1) receptors (Coulombe et al, 2002; Ehrenreich et al, 1992)
¥ endothelin-3 (ET-3, EDN3) (Coulombe et al, 2002)
¥¥ endothelin-3 (ET-3, EDN3) receptors (Coulombe et al, 2002)
¥ ENPP-2 (Tsuchiya S et al, 2009)
¥ ENPP-5 (Tsuchiya S et al, 2009)
¥¥ erythropoietin (Epo, Ep, ECSA, erythroid colony stimulating activity, ESF, erythropoiesis stimulating factor) receptors (EPOR) (Tsuchiya S et al, 2009)
¥ estrogen receptors (Kim et al, 2001)

¥ FAS ligand (FASL, FASLG, APT1LG1, apoptosis antigen ligand 1, CD95 ligand, CD95L, APO-1 ligand, APTL, Apoptosis antigen ligand, TNF ligand superfamily member 6, TNFSF6, CD178) (Nakamura R et al, 2005)
¥ Fc-epsilon R1 (Toru et al, 1996; Okayama et al, 1995, 1998; Plaut et al, 1989; Shimizu et al, 2002; Cherwinski et al, 2005)
¥ Fc-gamma R2B (Malbec et al, 2002)
¥ ferritin (H-Ferritin, FTH1, FTH, L-Ferritin, FTL, CD-GF, carcinoma-derived growth factor) (Tsuchiya S et al, 2009)
¥ FGF-10 (fibroblast growth factor-10, KGF-2, Keratinocyte growth factor-2) (Artuc et al, 2002)
¥ FGF-12 (Fibroblast growth factor-12, FHF-1, fibroblast growth factor homologous factor-1) (Nakayama et al, 2008)
¥ fibronectin (FN, fibronectin-1, FN1, LETS, large external transformation-sensitive protein, Fibroblast surface antigen, SF antigen, SFA, CIg, CI globulin, cold-insoluble globulin, CSP, galactoprotein A, MSF, migration stimulating factor, Z protein) (Tsuchiya S et al, 2009)
¥¥ fibronectin (FN, fibronectin-1, FN1, LETS, large external transformation-sensitive protein, Fibroblast surface antigen, SF antigen, SFA, CIg, CI globulin, cold-insoluble globulin, CSP, galactoprotein A, MSF, migration stimulating factor, Z protein) receptors (VLA5, VLA-4) (Lorentz et al, 2002; Fehlner-Gardiner et al, 1996)
¥ Fibulin-1 (FBLN1, BM-90, basement membrane protein 90) (Tsuchiya S et al, 2009)
¥ Ft1 (fused toes) (Tsuchiya S et al, 2009)

¥ gadd34 (growth arrest and DNA damage induced gene-34, MyD116) (Lora et al, 2003)
¥ gadd45 (growth arrest and DNA damage induced gene-45) (Nakamura R et al, 2005)
¥ gadd153 (growth arrest and DNA damage induced gene-153, DDIT3, DNA damage-inducible transcript-3, CHOP, C/EBP-homologous protein, CHOP-10, C/EBP-homologous protein-10, C/EBP-zeta, CCAAT/enhancer binding protein zeta) (Nakamura R et al, 2005)
¥ galanin (GAL, GALN, GLNN) (Tsuchiya S et al, 2009)
¥¥ galanin (GAL, GALN, GLNN) receptors (Tsuchiya S et al, 2009)
¥ Galectin-1 (Gal-1, LGALS1, galactose-specific soluble lectin 1, L-14-I, Lactose-binding lectin 1, S-lac lectin-1, Galaptin, 14 kDa beta-galactoside-binding lectin, 14 kDa lectin, HLBP14, 14 kDa laminin binding protein) (Sena et al, 2006; Gil et al, 2006; Tsuchiya S et al, 2009; Suzuki Y et al, 2008; Estofolete et al, 2011)
¥ Galectin-3 (Gal-3, LGALS3, galactose-specific soluble lectin 3, Mac-2, macrophage galactose-specific lectin-2, L-29, CBP-35, carbohydrate binding protein-35, IgE binding factor epsilon, Epsilon BP) (Tsuchiya S et al, 2009; Estofolete et al, 2011; Suzuki Y et al, 2008)
¥¥ Galectin-3 (Gal-3, LGALS3, galactose-specific soluble lectin 3, Mac-2, macrophage galactose-specific lectin-2, L-29, CBP-35, carbohydrate binding protein-35, IgE binding factor epsilon, Epsilon BP) receptors (Suzuki Y et al, 2008)
¥ Galectin-4 (Gal-4, LGALS4, galactose-specific soluble lectin 4, lectin galactoside-binding soluble 4, L-36, L-36LBP, Lactose-binding lectin 4, NY-CO-27 antigen) (Tsuchiya S et al, 2009)
¥ Galectin-9 (LGALS9, galactose-specific soluble lectin 9, Ecalectin, UAT, urate transporter, Tim-3L, Tim-3 ligand) (Tsuchiya S et al, 2009)
¥ GAP43 (growth associated protein 43, B-50, 3D5 antigen, F1, pp46, P57, 7-5, p54(Ca)p, GAP48, neuromodulin) (Tsuchiya S et al, 2009)
¥ gas-1 (Growth arrest-specific gene-1) (Lora et al, 2003; Tsuchiya S et al, 2009)
¥ gas-3 (Growth arrest-specific gene-3, peripheral myelin protein-22, PMP22, PAS2) (Tsuchiya S et al, 2009)
¥¥ gas-6 (Growth arrest-specific gene-6, Growth-potentiating factor, GPF, AXLLG, axl receptor tyrosine kinase ligand, AXSF, axl stimulatory factor) receptors (axl) (Tsuchiya S et al, 2009)
¥ gas-8 (Tsuchiya S et al, 2009)
¥ GDF9 (growth/differentiation factor-9) (Tsuchiya S et al, 2009)
¥¥ ghrelin (GHRL, GRLN, MTLRP, motilin-related peptide, GHSR ligand, growth hormone secretagogue receptor ligand, GGDT, ghrelin gene-derived transcript) receptors (GHSR, growth hormone secretagogue receptor, Growth hormone secretagogue receptor type 1, GHSR-1a, growth hormone secretagogue receptor 1a, GHSR-1b, growth hormone secretagogue receptor 1b, GRLNR, GH-releasing peptide receptor) (Dass NB et al, 2003; Hirayama et al, 2010)
¥ GITR (glucocorticoid induced tumor necrosis factor receptor family related gene, AITR, activation-inducible TNFR, TNFRSF18, TNF receptor superfamily member 18, CD357) (Nakae et al, 2006)
¥ glycodelin (PP14, placental protein 14, GdA, Glycodelin-A, GdS, Glycodelin-S, PAEP, progestagen-associated endometrial protein, pregnancy-associated endometrial alpha-2-globulin, progestagen-dependent endometrial protein) (Lang and Venkatraman, 2007)
¥ GM-CSF (Granulocyte-macrophage colony stimulating factor, BPA, burst promoting activity, CSF-2, colony stimulating factor-2, GM-CSA, Granulocyte-macrophage colony stimulating activity, MGI-1GM, macrophage-granulocyte inducer, Pluripoietin-alpha) (McCurdy et al, 2003; Gilchrest et al, 2003; Okayama et al, 1998; Lin et al, 2003; Bullock and Johnson, 1996; Nilsson et al, 1995; Wodnar-Filipowicz et al, 1989; Burd et al, 1989; Meade et al, 1993; Kulka et al, 2008; Schmidt et al, 2009; Kondo et al, 2008; Niyonsaba et al, 2010)
¥¥ GM-CSF (Granulocyte-macrophage colony stimulating factor, BPA, burst promoting activity, CSF-2, colony stimulating factor-2, GM-CSA, Granulocyte-macrophage colony stimulating activity, MGI-1GM, macrophage-granulocyte inducer, Pluripoietin-alpha) receptors (CSF2RA, CSF-2 receptor-A, Colony stimulating factor-2 receptor A, Colony stimulating factor-2 receptor-alpha, CSF2R, CSF-2 receptor, Colony stimulating factor-2 receptor, CSF2RY, GMCSFR, GM-CSF receptor, CDw116, CD116; common beta, beta c, betac, common cytokine receptor-beta, cytokine receptor common subunit beta, IL3RB, IL3 receptor subunit beta, IL3R-beta, IL5RB, IL5 receptor subunit beta, IL5R-beta, GM-CSF receptor subunit beta, CSF2RB, colony stimulating factor-2 receptor-beta, CD131) (Bressler et al, 1989; Welker et al, 1997; Meade et al, 1993; Tsuchiya S et al, 2009; Yang et al, 2009)
¥¥ gp130 (IL6ST, IL6 signal transducer, IL6R-beta, IL6RB, CDw130, CD130) (Tsuchiya S et al, 2009; Traum D et al, 2012)
¥ GPR44 (G-protein-coupled receptor-44, CRTH2, chemoattractant receptor-homologous molecule expressed on Th2 cells, DL1R, CD294) (Boehme et al, 2009)
¥¥ GPR77 (G-protein-coupled receptor-77, C5L2, C5a receptor-like 2, complement 5a-like receptor 2) (Otto et al, 2004)
¥ Granzyme B (GZMB, Granzyme 2, serine protease B, SE-2, serine esterase-2, CSP-B, cytotoxic serine protease B, CCP1, cytotoxic cell protease-1, Asp-ase, CGL1, cathepsin G-like-1, CTLA-1, cytotoxic T-lymphocyte-associated serine esterase-1, fragmentin-2, RNKP1, rat natural killer protease-1) (Pardo et al, 2007; Strik et al, 2007)

¥ HB-EGF (Heparin binding EGF-like factor, Heparin binding EGF-like growth factor, Hegfl, par-2, prostate apoptosis response protein 2, DTR, Diphtheria toxin receptor) (Artuc et al, 2002)
¥ HDGF (hepatoma-derived growth factor, HuHGF, HMG1L2, high mobility group protein 1-like-2; TDRM1 protein) (Tsuchiya S et al, 2009)
¥ HDGF-related protein-2 (HRP-2) (Tsuchiya S et al, 2009)
¥ HER3 (human EGF receptor-3, EGF receptor 3, epidermal growth factor receptor 3, erbB3, p180erbB3) (Tsuchiya S et al, 2009)
¥¥ HGF (hepatocyte growth factor, HGF/SF, Hepatocyte growth factor-scatter factor, F-TCF, fibroblast tumor cytotoxic factor, HPTA, Hepatopoietin A, SF, scatter factor, TCF, tumor cytotoxic factor, Lung fibroblast-derived mitogen) receptors (met, HGFR, HGF receptor, hepatocyte growth factor receptor, scatter factor receptor) (Fehlner-Gardiner et al, 1999)
¥ histamine receptor type 4 (Nakayama et al, 2004)
¥¥ histatin-5 (Hst 5; histidine-rich protein-5; HRP-5, histidine-rich polypeptide-5) receptors (Yoshida M et al, 2001)
¥¥ histatin-8 (Hst 8; histidine-rich protein-8) receptors (Yoshida M et al, 2001)
¥ hsp70 (heat shock protein 70) (Mortaz et al, 2006

¥ ICAM-2 (intercellular adhesion molecule 2, Ly60, CD102) (Tsuchiya S et al, 2009)
¥ ID4 (Inhibitor of DNA binding-4, inhibitor of DNA binding/differentiation-4, IDB4) (Tsuchiya S et al, 2009)
¥ IFI16 (interferon-induced protein 16, interferon-gamma-inducible protein-16, IFNGIP1, interferon-gamma-inducible protein-1, PYHIN2) (Dawson and Trapani, 1995)
¥ IFN-alpha (interferon-alpha, Alpha-Interferon, aIFN, B-cell interferon, Leukocyte interferon, LeIFN, Lymphoblast interferon, LyIFN-alpha) (Swieter et al, 1989; Crivellato et al, 2002; Bissonnette and Befus, 1990)
¥¥ IFN-beta (Beta-Interferon, Interferon-beta, bIFN, Fibroblast interferon, Fi-IFN, F-IFN) receptors (IFNAR1, IFN-alpha/beta receptor 1, interferon (alpha, beta and omega) receptor 1, IFN-alphaR1, IFRC, IFNAR, IFNAR2, IFN-alpha/beta receptor 2, interferon (alpha, beta and omega) receptor 2, IFN-alphaR2, IFNABR) (Cho JJ et al, 1998; Swieter et al, 1989; Crivellato et al, 2002; Bissonnette and Befus, 1990)
¥ IFN-gamma (IFNG, interferon-gamma, Gamma-Interferon, gIFN) (Burd et al, 1989; Gupta et al, 1996; Bulanova et al, 2009)
¥¥ IFN-gamma (IFNG, interferon-gamma, Gamma-Interferon, gIFN) receptors (IFNGR1, IFN-gamma receptor-1, IFN-gamma-R1, interferon-gamma receptor 1, immune interferon receptor 1, AVP type 2, antiviral protein type 2, CD119, IFNGR2, interferon-gamma receptor 2, IFN-gamma receptor 2, IFN-gamma-R2, IFGR2, IFNGT1, interferon-gamma transducer 1) (Kirshenbaum et al, 1998; Nafziger et al, 1990; Coleman et al, 1991; Bissonnette and Befus, 1990; Okumura et al, 2009)
¥ IGF-2 (Insulin-like growth factor-2, Growth-promoting activity for vascular endothelial cells, T3M-11-derived growth factor, ILGF2, MSA, multiplication stimulating activity, NSILA, non-suppressible insulin-like activity, Somatomedin A, sulfation factor, SGF, skeletal growth factor, HP1-SMP, HP3-SMP, Somatomedin/insulin-like growth factor-like polypeptides, C11orf43, chromosome 11 open reading frame 43) (Tsuchiya S et al, 2009)
¥ IGFBP4 (Insulin-like growth factor binding protein-4, IGF binding protein-4, Colon cancer cell growth inhibitor, HT29-IGFBP, HT29 insulin-like growth factor binding protein) (Tsuchiya S et al, 2009)
¥ IGFBP5 (Insulin-like growth factor binding protein-5, IGF binding protein-5) (Tsuchiya S et al, 2009)
¥ IGFBP6 (Insulin-like growth factor binding protein-6, IGF binding protein-6) (Tsuchiya S et al, 2009)
¥ IL1-alpha (IL1A, interleukin-1-alpha, IL1F1, Interleukin-1 family member 1, BAF, B-cell activating factor, BCAF, B-cell activating factor, EP, endogenous pyrogens, LAF, lymphocyte activating factor, LEM, leukocyte endogenous mediator, MCF, mononuclear cell factor, MNCF, mononuclear cell factor, MP, mitogenic protein, TRF-3, T-cell replacing factor-3, Tumor inhibitory factor-2), IL1-beta (McCurdy et al, 2003; Babina et al, 2004; Supajatura et al, 2002; Nilsson et al, 1995; Burd et al, 1989; Lin et al, 2002; Mšller et al, 1998)
¥ IL1-beta (IL1B, interleukin-1-beta, IL1F2, Interleukin-1 family member 2, Catabolin, H1, Hematopoietin-1, IFN-beta inducing factor, Interleukin-beta, OAF, osteoclast activating factor) (Moulin D et al, 2007; Nagai K et al, 2012)
¥¥ IL1-beta (IL1B, interleukin-1-beta, IL1F2, Interleukin-1 family member 2, Catabolin, H1, Hematopoietin-1, IFN-beta inducing factor, Interleukin-beta, OAF, osteoclast activating factor) receptors (IL1RA, IL1R-alpha, IL1 receptor-alpha; interleukin-1 receptor-alpha, IL1R1, IL1 receptor type 1, Interleukin-1 receptor 1, IL1 receptor R1, CD121a; IL1RB, IL1R-beta, IL1 receptor-beta; interleukin-1 receptor-beta, IL1R2, IL1 receptor type 2, Interleukin-1 receptor 2, IL1 receptor R2, CD121b, AURA31, augmented in rheumatoid arthritis 31) (Ho LH et al, 2007; Iikura et al, 2007)
¥ IL1ra (IL1 receptor antagonist, IL1RN, IL1 inhibitor, IRAP, IL1 receptor antagonist protein, IL1 inhibitory activity, ILS, IL1F3, IL1 family member 3, DIRA, deficiency of the IL1 receptor antagonist) (Hagaman et al, 2001; Okayama et al, 2001)
¥¥ IL1 (interleukin-1) receptors (IL1RA, IL1R-alpha, IL1 receptor-alpha; interleukin-1 receptor-alpha, IL1R1, IL1 receptor type 1, Interleukin-1 receptor 1, IL1 receptor R1, CD121a; IL1RB, IL1R-beta, IL1 receptor-beta; interleukin-1 receptor-beta, IL1R2, IL1 receptor type 2, Interleukin-1 receptor 2, IL1 receptor R2, CD121b, AURA31, augmented in rheumatoid arthritis 31) (Kandere-Grzybowska et al, 2003; Subramanian and Bray, 1987; Hogaboam et al, 1993; Lorentz et al, 2000)
¥ IL2 (Interleukin-2, BF, blastogenic factor, EDF, eosinophil differentiation factor, KHF, killer cell helper factor, LMF, lymphocyte mitogenic factor, LPF, lymphocyte proliferation factor, MAF-C I, macrophage-activating factor for cytotoxicity I, PFC-EA, plaque forming cell enhancing factor, SCIF, secondary cytotoxic T-cell inducing factor, TCGF, T-cell growth factor, TCPA, T colony-promoting activity, TDF, thymocyte differentiation factor, T-LPF, T-lymphocyte promotor factor, TMF, thymocyte mitogenic factor, T-cell maturation factor, T-cell mitogenic factor, TRF-3, T-cell replacing factor-3, TSF, thymocyte stimulating factor) (Oh et al, 2001; Kitaura et al, 2000; Niyonsaba et al, 2010)
¥¥ IL2 (Interleukin-2, BF, blastogenic factor, EDF, eosinophil differentiation factor, KHF, killer cell helper factor, LMF, lymphocyte mitogenic factor, LPF, lymphocyte proliferation factor, MAF-C I, macrophage-activating factor for cytotoxicity I, PFC-EA, plaque forming cell enhancing factor, SCIF, secondary cytotoxic T-cell inducing factor, TCGF, T-cell growth factor, TCPA, T colony-promoting activity, TDF, thymocyte differentiation factor, T-LPF, T-lymphocyte promotor factor, TMF, thymocyte mitogenic factor, T-cell maturation factor, T-cell mitogenic factor, TRF-3, T-cell replacing factor-3, TSF, thymocyte stimulating factor) receptors (IL2RA, interleukin-2 receptor-alpha; IL2R-alpha; IL2 receptor-alpha, IL2R, interleukin-2 receptor, TAC antigen, TCGFR, T-cell growth factor receptor, IDDM10, insulin-dependent diabetes mellitus 10, CD25; Ly43, lymphocyte antigen 43, OX39, IL2RB, interleukin-2 receptor-beta; IL2R-beta; IL2 receptor-beta, CD122; IL2RG, IL2 receptor-gamma, interleukin-2 receptor-gamma, IL2R-gamma, common gamma, gammac, gamma common, common cytokine receptor-gamma; cytokine receptor common subunit gamma, CD132, SCIDX1, X-linked severe combined immunodeficiency-1) (Rubinchik et al, 1995; Tasaka et al, 1994)
¥ IL3 (Interleukin-3, 20-alpha-hydroxysteroid dehydrogenase inducing factor, BPA, burst promoting activity, CFU-S, colony-forming unit spleen, CSF-2-alpha, colony stimulating factor-2-alpha, CSF-2-beta, colony stimulating factor-2-beta, ECSF, erythroid colony stimulating factor, Eo-CSF, eosinophil colony stimulating factor, HCGF, Hematopoietic cell growth factor, HP2, Hematopoietin-2, HPGF, hematopoietic cell growth factor, MCGF, mast cell growth factor, MCSA, multi-colony stimulating activity, Meg-CSF, megakaryocyte colony stimulating factor, MGF, mast cell growth factor, Mixed colony stimulating factor, Multi-CSF, Multi-colony stimulating factor, multi-HGF, multilineage hemopoietic growth factor, Multipoietin, NC cell growth factor, natural cytotoxic cell growth factor, Neutrophil-granulocyte colony stimulating factor, PSF, progenitor stimulating factor, PSH, panspecific hemopoietin, SAF, stem cell activating factor, Thy1 inducing factor) (Nilsson et al, 1995; Plaut et al, 1989; Wodnar-Filipowicz et al, 1989; Burd et al, 1989; Lorentz et al, 2000; Mšller et al, 1998; Razin et al, 1991; Kulka et al, 2008; Nakamura R et al, 2005; Spiegl et al, 2008)
¥¥ IL3 (Interleukin-3, 20-alpha-hydroxysteroid dehydrogenase inducing factor, BPA, burst promoting activity, CFU-S, colony-forming unit spleen, CSF-2-alpha, colony stimulating factor-2-alpha, CSF-2-beta, colony stimulating factor-2-beta, ECSF, erythroid colony stimulating factor, Eo-CSF, eosinophil colony stimulating factor, HCGF, Hematopoietic cell growth factor, HP2, Hematopoietin-2, HPGF, hematopoietic cell growth factor, MCGF, mast cell growth factor, MCSA, multi-colony stimulating activity, Meg-CSF, megakaryocyte colony stimulating factor, MGF, mast cell growth factor, Mixed colony stimulating factor, Multi-CSF, Multi-colony stimulating factor, multi-HGF, multilineage hemopoietic growth factor, Multipoietin, NC cell growth factor, natural cytotoxic cell growth factor, Neutrophil-granulocyte colony stimulating factor, PSF, progenitor stimulating factor, PSH, panspecific hemopoietin, SAF, stem cell activating factor, Thy1 inducing factor) receptors (IL3RA, interleukin-3 receptor-alpha, IL3R-alpha, common beta, beta c, betac, common cytokine receptor-beta, cytokine receptor common subunit beta, IL3RB, IL3 receptor subunit beta, IL3R-beta, IL3 receptor subunit beta; interleukin-3 receptor-beta, IL5RB, IL5 receptor subunit beta, IL5R-beta, GM-CSF receptor subunit beta, CSF2RB, colony stimulating factor-2 receptor-beta, CD131) (Gebhardt et al, 2002; Renold et al, 1987; Haig et al, 1988; Lorentz et al, 2003; Bressler et al, 1989; Matsuura and Zetter, 1989; Kondo et al, 2008)
¥ IL4 (Interleukin-4, BCDF-epsilon, B-cell differentiation factor-epsilon, BCDF-gamma, B-cell differentiation factor-gamma, BCGF-gamma, B-cell growth factor-gamma, BCGF-1, B-cell growth factor-1, Binetrakin, BSF-1, B-cell stimulating factor-1, BSF-p1, B-cell stimulating factor p1, EL4-BCGF, EL4 B-cell growth factor, HCGF, Hodgkin's cell growth factor, IgE-EF, IgE enhancing factor, IgG1-enhancing factor, IgG1-induction factor, LMW-BCGF, low molecular weight B-cell growth factor, MaGEF, Mast cell growth enhancing factor, MCGF-2, mast cell growth factor-2, MFF, macrophage fusion factor, Pitrakinra, TCGF-2, T-cell growth factor-2) (Brown et al, 1987; Kimura et al, 2002; Brightling et al, 2003; Bullock and Johnson, 1996; Smith et al, 1994; Plaut et al, 1989; Okayama et al, 1998; Bradding et al, 1994; Mšller et al, 1998; Gessner et al, 2005; Zhang et al, 2007; Kondo et al, 2008; Nakamura R et al, 2005; Ketavarapu et al, 2008; Nakano et al, 2009; Bulanova et al, 2009; Schmidt et al, 2009; Ršnnberg E et al, 2010; He S et al, 2010; Niyonsaba et al, 2010)
¥¥ IL4 (Interleukin-4, BCDF-epsilon, B-cell differentiation factor-epsilon, BCDF-gamma, B-cell differentiation factor-gamma, BCGF-gamma, B-cell growth factor-gamma, BCGF-1, B-cell growth factor-1, Binetrakin, BSF-1, B-cell stimulating factor-1, BSF-p1, B-cell stimulating factor p1, EL4-BCGF, EL4 B-cell growth factor, HCGF, Hodgkin's cell growth factor, IgE-EF, IgE enhancing factor, IgG1-enhancing factor, IgG1-induction factor, LMW-BCGF, low molecular weight B-cell growth factor, MaGEF, Mast cell growth enhancing factor, MCGF-2, mast cell growth factor-2, MFF, macrophage fusion factor, Pitrakinra, TCGF-2, T-cell growth factor-2) receptors (IL4RA, IL4R-alpha, interleukin-4 receptor-alpha, IL4R, interleukin-4 receptor, CD124) (Mosmann et al, 1986; Schmitt et al, 1986; Babina et al, 2004; Lora et al, 2003; Okayama et al, 2009)
¥ IL5 (Interleukin-5, B151-TRF, B151 T-cell replacing factor, BCDF, B-cell differentiation factors, BCDF-alpha, B-cell differentiation factor-alpha, BCDF-mu, B-cell differentiation factor-mu, BCGF-2, B-cell growth factor-2, DL-BCGF, Dennert line B-cell growth factor, BGDF, B-cell growth and differentiation factor, CFU-Eo GSF, colony-forming unit eosinophil growth stimulating factor, EDF, eosinophil differentiation factor, Eo-CSF, Eosinophil colony stimulating factor, Eo-DF, eosinophil differentiation factor, ESP, eosinophil stimulation promoter, IgA-EF, IgA enhancing factor, KHF, killer helper factor, TRF-1, T-cell replacing factor-1) (Kimura et al, 2002; Babina et al, 2004; Lorentz et al, 2003; Masuda et al, 2002; Aoki et al, 2003; Plaut et al, 1989; Okayama et al, 1998; Burd et al, 1989; Lorentz et al, 2000; Macey MR et al, 2010)
¥¥ IL5 (Interleukin-5, B151-TRF, B151 T-cell replacing factor, BCDF, B-cell differentiation factors, BCDF-alpha, B-cell differentiation factor-alpha, BCDF-mu, B-cell differentiation factor-mu, BCGF-2, B-cell growth factor-2, DL-BCGF, Dennert line B-cell growth factor, BGDF, B-cell growth and differentiation factor, CFU-Eo GSF, colony-forming unit eosinophil growth stimulating factor, EDF, eosinophil differentiation factor, Eo-CSF, Eosinophil colony stimulating factor, Eo-DF, eosinophil differentiation factor, ESP, eosinophil stimulation promoter, IgA-EF, IgA enhancing factor, KHF, killer helper factor, TRF-1, T-cell replacing factor-1) receptors (IL5RA, IL5R-alpha, interleukin-5 receptor, interleukin-5 receptor-alpha, IL5RB, IL5R-beta, interleukin-5 receptor-beta, CD125, CDw125, common beta, beta c, betac, common cytokine receptor-beta, cytokine receptor common subunit beta, IL3RB, IL3 receptor subunit beta, IL3R-beta, IL5RB, IL5 receptor subunit beta, IL5R-beta, GM-CSF receptor subunit beta, CSF2RB, colony stimulating factor-2 receptor-beta, CD131) (Lora et al, 2003)
¥ IL6 (interleukin-6, 26 kDa protein, BSF-2, B-cell stimulating factor-2, CDF, CAT development factor, choline acetyltransferase development factor, Cytolytic differentiation factor for T-lymphocytes, FDGI, fibroblast-derived growth inhibitor, hybridoma growth factor, HPGF, hybridoma/plasmacytoma growth factor, HSF, hepatocyte stimulating factor, HSF-1, hepatocyte stimulating factor-1, ILHP1, Interleukin-hemopoietin-1, MGI-2A, Macrophage-granulocyte inducer-2A, Myeloma GF, myeloma growth factor, NKAF, natural killer cell activating factor, TAF, T-cell activating factor, Thymocyte growth factor, TSF, thymocyte stimulating factor) (Azzolina et al, 2003; Kempuraj et al, 2003; Babina et al, 2004; Nilsson et al, 1995; Plaut et al, 1989; Kandere-Grzybowska et al, 2003; Supajatura et al, 2002; Burd et al, 1989; HŸltner et al, 1989; Lorentz et al, 2000; Mortaz et al, 2006; Nakano et al, 2009; Ho LH et al, 2007; Kondo et al, 2008; Moulin D et al, 2007; Bulanova et al, 2009; Yang et al, 2009; Ršnnberg E et al, 2010; Niyonsaba et al, 2010; Nagai K et al, 2012)
¥¥ IL6 (interleukin-6, 26 kDa protein, BSF-2, B-cell stimulating factor-2, CDF, CAT development factor, choline acetyltransferase development factor, Cytolytic differentiation factor for T-lymphocytes, FDGI, fibroblast-derived growth inhibitor, hybridoma growth factor, HPGF, hybridoma/plasmacytoma growth factor, HSF, hepatocyte stimulating factor, HSF-1, hepatocyte stimulating factor-1, ILHP1, Interleukin-hemopoietin-1, MGI-2A, Macrophage-granulocyte inducer-2A, Myeloma GF, myeloma growth factor, NKAF, natural killer cell activating factor, TAF, T-cell activating factor, Thymocyte growth factor, TSF, thymocyte stimulating factor) receptors (IL6RA, IL6R-alpha, IL6R, interleukin-6 receptor, interleukin-6 receptor-alpha, CD126, IL6ST, IL6 signal transducer, interleukin-6 signal transducer, IL6R-beta, interleukin-6 receptor-beta, IL6RB, CDw130, CD130) (Kinoshita et al, 1999)
¥ IL8 (interleukin-8, SCYB8, 3-10C, 9E3, ANAP, anionic neutrophil-activating peptide, Chemotaxin, CEF-4, CT/IL8, CXCL8, CXC chemokine ligand 8, chemokine (C-X-C motif) ligand 8, EDNAP, endothelial-derived neutrophil-activating peptide, EMF-1, embryo fibroblast protein 1, Emoctakin, ENAP, Endothelial cell neutrophil-activating peptide, FDNAP, Fibroblast-derived neutrophil-activating peptide, FINAP, fibroblast-derived neutrophil-activating protein, GCF, granulocyte chemotactic factor, GCP, granulocyte chemotactic peptide, LAI, leukocyte adhesion inhibitor, LCF, lymphocyte chemotactic factors, LDNAP, leukocyte-derived neutrophil-activating peptide, leukocyte inhibitory factor, LUCT, lung carcinoma-derived chemotaxin, LYNAP, lymphocyte-derived neutrophil-activating peptide, MDNAP, monocyte-derived neutrophil-activating peptide, MDNCF, monocyte-derived neutrophil chemotactic factor, MOC, monocyte-derived chemotaxin, MONAP, monocyte-derived neutrophil-activating peptide, NAF, neutrophil-activating factor, NAP-1, neutrophil-activating protein-1, NCF, neutrophil chemotactic factor, NCP, neutrophil chemotactic protein, PLF, psoriatic leukotactic factor, TCF, T-cell chemotactic factor, TSG-1, Tumor necrosis factor-stimulated gene sequence-1) (Kempuraj et al, 2003; Babina et al, 2004; Grabbe et al, 1994; Feoktistov et al, 2003; Lin et al, 2000; Mšller et al, 1993; Selvan et al, 1994; Lorentz et al, 2000; Kulka et al, 2008; Sheen et al, 2007; Castellani et al, 2007; Fischer et al, 2006; Iikura et al, 2007; Lappalainen J et al, 2011)
¥¥ IL8 (interleukin-8, SCYB8, 3-10C, 9E3, ANAP, anionic neutrophil-activating peptide, Chemotaxin, CEF-4, CT/IL8, CXCL8, CXC chemokine ligand 8, chemokine (C-X-C motif) ligand 8, EDNAP, endothelial-derived neutrophil-activating peptide, EMF-1, embryo fibroblast protein 1, Emoctakin, ENAP, Endothelial cell neutrophil-activating peptide, FDNAP, Fibroblast-derived neutrophil-activating peptide, FINAP, fibroblast-derived neutrophil-activating protein, GCF, granulocyte chemotactic factor, GCP, granulocyte chemotactic peptide, LAI, leukocyte adhesion inhibitor, LCF, lymphocyte chemotactic factors, LDNAP, leukocyte-derived neutrophil-activating peptide, leukocyte inhibitory factor, LUCT, lung carcinoma-derived chemotaxin, LYNAP, lymphocyte-derived neutrophil-activating peptide, MDNAP, monocyte-derived neutrophil-activating peptide, MDNCF, monocyte-derived neutrophil chemotactic factor, MOC, monocyte-derived chemotaxin, MONAP, monocyte-derived neutrophil-activating peptide, NAF, neutrophil-activating factor, NAP-1, neutrophil-activating protein-1, NCF, neutrophil chemotactic factor, NCP, neutrophil chemotactic protein, PLF, psoriatic leukotactic factor, TCF, T-cell chemotactic factor, TSG-1, Tumor necrosis factor-stimulated gene sequence-1) receptors (IL8RA, IL8R-alpha, interleukin-8 receptor-alpha; interleukin-8 receptor type A, IL8R1, IL8 receptor-1, interleukin-8 receptor type 1, CMKAR1, chemokine-alpha receptor 1, CXCR1, CD181, IL8RB, IL8R-beta, interleukin-8 receptor-beta; interleukin-8 receptor type B, IL8R2, IL8 receptor-2, interleukin-8 receptor type 2, CMKAR2, chemokine-alpha receptor 2, CXCR2, CD182) (Lippert et al, 1998; Nilsson et al, 1999; Ochi et al, 1999)
¥ IL9 (Interleukin-9, MCGF, mast cell growth factor, MEA, mast cell growth enhancing activity, Megakaryoblast growth factor, P40, TCGF-3, T-cell growth factor-3) (Stassen et al, 2001; HŸltner et al, 2000; Lorentz et al, 2000; Nakamura R et al, 2005)
¥¥ IL9 (Interleukin-9, MCGF, mast cell growth factor, MEA, mast cell growth enhancing activity, Megakaryoblast growth factor, P40, TCGF-3, T-cell growth factor-3) receptors (IL9R, interleukin-9 receptor, IL9 receptor, CD129) (Matsuzawa et al, 2003; Lora et al, 2003; HŸltner et al, 1989; HŸltner and Mšller, 1990)
¥ IL10 (interleukin-10, B-TCGF, B-cell derived T-cell growth factor, CSIF, cytokine synthesis inhibitory factor, TGIF, T-cell growth inhibitory factor) (Masuda et al, 2002; Bullock and Johnson, 1996; Supajatura et al, 2002; Ishizuka et al, 1999; Royer et al, 2001)
¥¥ IL10 (interleukin-10, B-TCGF, B-cell derived T-cell growth factor, CSIF, cytokine synthesis inhibitory factor, TGIF, T-cell growth inhibitory factor) receptors (IL10R, IL10R1, IL10RA, IL10 receptor-alpha, IL10R-alpha, interleukin-10 receptor-alpha; interleukin-10 receptor, CD210, CD210a, CDw210a; IL10R2, IL10RB, IL10R-beta, IL10 receptor-beta, interleukin-10 receptor-beta, CRF2-4, cytokine receptor family 2 member 4, CRFB4; CDw210b) (Thompson-Snipes et al, 1991; et al, 1992; Arock et al, 1996; Royer et al, 2001; Traum D et al, 2012)
¥ IL11 (Interleukin-11, AGIF, adipogenesis inhibitory factor, HPAEC survival factor, human pulmonary artery endothelial cell-derived survival factor, Megakaryocyte colony stimulating factor, Plasmacytoma stimulatory activity, Oprelvekin, Neumega) (Sayama et al, 2002)
¥ IL12 (IL12A, IL12-alpha IL12B, IL12-beta, IL12-p35, IL12-p40, IL12-p70, Interleukin-12, Interleukin-12A, Interleukin-12B, CLMF, cytotoxic lymphocyte maturation factor, NKSF, natural killer cell stimulatory factor, NKSF1, natural killer cell stimulatory factor-1, NKSF2, natural killer cell stimulatory factor-2, TcMF, CTL maturation factor, TSF, T-cell stimulating factor) (Coulombe et al, 2002; Smith et al, 1994; Mšller et al, 1998; Ršnnberg E et al, 2010)
¥¥ IL12 (IL12A, IL12-alpha IL12B, IL12-beta, IL12-p35, IL12-p40, IL12-p70, Interleukin-12, Interleukin-12A, Interleukin-12B, CLMF, cytotoxic lymphocyte maturation factor, NKSF, natural killer cell stimulatory factor, NKSF1, natural killer cell stimulatory factor-1, NKSF2, natural killer cell stimulatory factor-2, TcMF, CTL maturation factor, TSF, T-cell stimulating factor) receptors (IL12RB1, IL12R-beta-1; interleukin-12 receptor-beta-1, IL12R, interleukin-12 receptor, IL12RB, IL12R-beta, interleukin-12 receptor-beta, CD212; IL12RB2, interleukin-12 receptor-beta-2; IL12R-beta-2) (Gupta et al, 1996; Smith et al, 1994; Zhang et al, 2007)
¥ IL13 (Interleukin-13, NC30, P600) (Brightling et al, 2003; Lorentz et al, 2003; Masuda et al, 2002; Toru et al, 1998; Jaffe et al, 1996; Burd et al, 1995; Supajatura et al, 2002; Lorentz et al, 2000; Stassen et al, 2001; Gessner et al, 2005; Obara et al, 2002; Nakamura et al, 2002; Cherwinski et al, 2005; Nakano et al, 2009; Bulanova et al, 2009; Yang et al, 2009; Schmidt et al, 2009; Ršnnberg E et al, 2010; Ho LH et al, 2007; Iikura et al, 2007; Kondo et al, 2008; He S et al, 2010; Nagai K et al, 2012)
¥¥ IL15 (Interleukin-15, IL-T, Interleukin T) receptors (IL15RA, IL15R-alpha, CD215) (Masuda et al, 2001)
¥ IL16 (Interleukin-16, Lymphocyte chemoattractant factor, LCF) (Rumsaeng et al, 1997; Laberge et al, 1999; Lorentz et al, 2000)
¥¥ IL16 (Interleukin-16, Lymphocyte chemoattractant factor, LCF) receptors (Qi et al, 2002)
¥ IL17 (Interleukin-17, IL17A, interleukin-17A) (de Boer et al, 2010; Hueber AJ et al, 2010)
¥ IL17F (interleukin-17F, ML-1) (de Boer et al, 2010)
¥ IL18 (interleukin-18, IGIF, IFN-gamma inducing factor, IL1-gamma, IL1F4, IL1 family member 4, Iboctadekin) (Lorentz et al, 2000; Darimont et al, 2008; Tsuchiya S et al, 2009)
¥¥ IL18 (interleukin-18, IGIF, IFN-gamma inducing factor, IL1-gamma, IL1F4, IL1 family member 4, Iboctadekin) receptors (IL18R1, interleukin-18 receptor-1, IL18R-alpha, IL18RA, interleukin-18 receptor-alpha, IL1Rrp, IL1 receptor-related protein, IL1R5, Interleukin-1 receptor 5, IL1 receptor R5, CD218a, CDw218a) (Ho LH et al, 2007; Iikura et al, 2007; Kondo et al, 2008; Wiener et al, 2008)
¥ IL25 (interleukin-25, IL17E, interleukin-17E) (Ikeda et al, 2003; Wang YH et al, 2007)
¥¥ IL27 (interleukin-27, EBI-3, EBV induced gene-3, IL27A, IL27-alpha, interleukin-27-alpha, IL27B; IL27-beta, interleukin-27-beta, p28, IL27p28, IL30, interleukin-30) receptors (IL27RA, IL27 receptor-alpha, interleukin-27 receptor-alpha, IL27R, IL27R-alpha, CRL1, Cytokine receptor-like 1, WSX-1, TCCR, T-cell cytokine receptor, ZCytoR1) (Traum D et al, 2012)
¥ IL29 (IFN-lambda-1, interferon-lambda-1, IFNL1) (He S et al, 2010)
¥¥ IL29 (IFN-lambda-1, interferon-lambda-1, IFNL1) receptors (IL28RA, interleukin-28 receptor-alpha, IL28R-alpha, IL28R1, interleukin-28 receptor-1, IFN-lambda-R1, IFN-lambda receptor 1; interferon-lambda receptor-1, IFNLR1, IFNLR, interferon-lambda receptor, CRF2-12, Cytokine receptor family 2 member 12, LICR2, Likely Interleukin or Cytokine Receptor-2) (He S et al, 2010)
¥ IL31 (interleukin-31) (Niyonsaba et al, 2010)
¥¥ IL31 (interleukin-31) receptors (IL31RA, interleukin-31 receptor A; IL31 receptor-alpha; IL31R-alpha, GLMR, gp130-like monocyte receptor, GPL, gp130-like receptor, CRL3, cytokine receptor-like 3; OSMR, oncostatin M receptor, OSMRB, Oncostatin-M receptor-beta; OSMR-beta; Oncostatin-M-specific receptor subunit beta, IL31R-beta, IL31RB, IL31 receptor-beta, Interleukin-31 receptor-beta) (Yamaoka et al, 2009)
¥ IL32 (interleukin-32, IL32-alpha, IL32-beta, IL32-delta, IL32-epsilon, IL32-gamma, IL32-zeta, NK4, natural killer cell transcript 4, TAIF, tumor necrosis factor alpha-inducing factor, TAIFa, TAIF-alpha, TAIFb, TAIFc, TAIF-beta, TAIFd, TAIF-delta) (Netea et al, 2006)
¥ IL33 (interleukin-33, NFHEV, nuclear factor from high endothelial venules, C9orf26, chromosome 9 open reading frame 26, DVS27) (Hsu CL et al, 2010; Ohno et al, 2009; Hsu CL and Bryce PJ, 2012)
¥¥ IL33 (interleukin-33, NFHEV, nuclear factor from high endothelial venules, C9orf26, chromosome 9 open reading frame 26, DVS27) receptors (IL33R, IL1RL1, IL1 receptor-like-1, IL1R4, interleukin-1 receptor 4, IL1 receptor R4, T1, T1/ST2, ST2, ST2L, Fit-1, fos-induced transcript-1, Ly84, lymphocyte antigen 84, DER4, delayed early response gene 4) (Allakhverdi Z et al, 2007; Kondo et al, 2008; Manetti M et al, 2010; Moulin D et al, 2007; Iikura et al, 2007; Matsuda A et al, 2009, 2010; Xu D et al, 2008; Ho LH et al, 2007; Pushparaj et al, 2009; Kaieda S et al, 2010; Hsu CL et al, 2010; Baba Y et al, 2012)
¥ integrin-alpha-7 (Rosbottom et al, 2002; Tsuchiya S et al, 2009)
¥ integrin-beta-7 (Wright et al, 2002)

¥ jagged-1 (JAG1, JAGL1, jagged, Serrate-1) (Singh et al, 2000)
¥ JAM1 (Junctional adhesion molecule 1, JAM-A, Junctional adhesion molecule A, JCAM, Platelet F11 receptor, F11R, F11 receptor, platelet adhesion molecule 1, PAM-1, Ly106, lymphocyte antigen 106, CD321) (Florian S et al, 2006)

¥ KGF (keratinocyte growth factor, HBGF-7, heparin binding growth factor-7, FGF-7, fibroblast growth factor-7, palifermin) (Artuc et al, 2002)

¥ laminin and/or laminin receptors (Thompson et al, 1990, 1991)
¥ LATS2 (large tumor suppressor-2, warts) (Tsuchiya S et al, 2009)
¥ leptin (ob, ob/ob, obese protein, obesity factor, Metreleptin) (Taildeman et al, 2009)
¥¥ leptin (ob, ob/ob, obese protein, obesity factor, Metreleptin) receptors (LEPR, OBR, CD295, db, db/db, fatty, fa, fa/fa) (Taildeman et al, 2009)
¥ LIF (leukemia inhibitory factor; myeloid leukemia inhibitory factor, ABAE cell growth-inhibitory activity; CDF, cholinergic differentiation factor, CNDF, cholinergic neuronal differentiation factor, D-Factor, differentiation stimulating factor, DIA, differentiation inhibiting activity, DIF, differentiation inducing factor, DRF, Differentiation-retarding factor, ES cell growth factor, ESCGF, embryonic stem cell growth factor, GATS, growth stimulatory activity for TS1 cells, HILDA, human interleukin for Da cells, HSF-2, hepatocyte stimulating factor-2, HSF-3, hepatocyte stimulating factor-3, Lipoprotein lipase inhibitor, M1 differentiation inducing activity, MCGEF, mast cell growth-enhancing factor, MLPLI, melanoma-derived lipoprotein lipase inhibitor, OAF, osteoclast activating factor) (Marshall et al, 1993; Tanaka et al, 2001;l Dowsing et al, 2001)
¥¥ LIF (leukemia inhibitory factor; myeloid leukemia inhibitory factor, ABAE cell growth-inhibitory activity; CDF, cholinergic differentiation factor, CNDF, cholinergic neuronal differentiation factor, D-Factor, differentiation stimulating factor, DIA, differentiation inhibiting activity, DIF, differentiation inducing factor, DRF, Differentiation-retarding factor, ES cell growth factor, ESCGF, embryonic stem cell growth factor, GATS, growth stimulatory activity for TS1 cells, HILDA, human interleukin for Da cells, HSF-2, hepatocyte stimulating factor-2, HSF-3, hepatocyte stimulating factor-3, Lipoprotein lipase inhibitor, M1 differentiation inducing activity, MCGEF, mast cell growth-enhancing factor, MLPLI, melanoma-derived lipoprotein lipase inhibitor, OAF, osteoclast activating factor) receptors (LIFR, leukemia inhibitory factor receptor, LIF receptor, LIFR-alpha, leukemia inhibitory factor receptor-alpha, LIF receptor-alpha, LIFR-beta, LIF receptor-beta; leukemia inhibitory factor receptor-beta, CD118, IL6ST, IL6 signal transducer, IL6R-beta, IL6RB, CDw130, CD130) (Hiragun et al, 2000; Tanaka et al, 2001)
¥ LTBP1 (Latent TGF-beta binding protein-1) (Tsuchiya S et al, 2009)
¥ LTBP3 (Latent TGF-beta binding protein-3) (Inomata et al, 2005)
¥ LTBP4 (Latent TGF-beta binding protein-4, LTBP4S, LTBP4L) (Tsuchiya S et al, 2009)
¥ Lumican (LUM, LCN, LDC, corneal keratan sulfate proteoglycan 37B core protein, SLRR2D) (Tsuchiya S et al, 2009)
¥ luteinizing hormone beta Lhb (Tsuchiya S et al, 2009)

¥ MAFA (Mast-cell-function-associated antigen, MAFA-L, MAFA-like, CLEC15A, C-type lectin domain family 15 member A, KLRG1, killer cell lectin-like receptor G1) (Lamers et al, 1998; Guthmann et al, 1995)
¥ Maspin (mammary serpin, mammary serine protease inhibitor, Serpin B5, protease inhibitor-5, proteinase inhibitor-5, PI5) (Tsuchiya S et al, 2009)
¥ mast cell protease 1 (Tsuchiya S et al, 2009)
¥ mast cell protease 2 (Tsuchiya S et al, 2009)
¥ mast cell protease 4 (Tsuchiya S et al, 2009)
¥ mast cell protease 5 (Tsuchiya S et al, 2009)
¥ mast cell protease 6 (Tsuchiya S et al, 2009)
¥ M-CSF (macrophage colony stimulating factor, CSF-1, colony stimulating factor-1, CSF-HU, Urinary colony stimulating factor, MGF, macrophage growth factor, MGI-1M, macrophage-granulocyte inducer, op, osteopetrotic, toothless, tl, Lanimostim) (Nilsson et al, 1995; Nakamura et al, 2002; Tsuchiya S et al, 2009)
¥ Metallothionein-1 (metallothionein, MT-1) (Tsuchiya S et al, 2009)
¥ metallothionein-2 (Tsuchiya S et al, 2009)
¥ MHC class 2 (Warbrick et al, 1995; Frandji et al, 1995)
¥ MIA (melanoma inhibitory activity, CD-RAP, cartilage-derived retinoic acid-sensitive protein) (Tsuchiya S et al, 2009)
¥ MINCLE (Macrophage-inducible C-type lectin, CLECSF9, C-type lectin domain superfamily member 9, CLEC4E, C-type lectin domain family 4 member E, AURA24, augmented in rheumatoid arthritis 24) (Ribbing et al, 2011)
¥ MINOR (mitogen inducible nuclear orphan receptor, NR4A3, nuclear receptor subfamily 4 group A member 3, NOR1, neuron-derived orphan receptor-1, CHN, CSMF) (Zhang L et al, 2010)
¥ MMP-2 (matrix metalloproteinase-2, EC3.4.24.24, 70 kDa gelatinase, 72 kDa gelatinase, 72 kDa metalloproteinase, collagenase type 4, collagenase type 4A, 72 kDa type IV collagenase, Gelatinase 72 kDa, Gelatinase A, Type IV collagenase, Type IVA collagenase, neutrophil gelatinase) (Yoshikawa et al, 1999; Fang et al, 1999; Tsuchiya S et al, 2009)
¥ MMP-9 (matrix metalloproteinase-9, EC3.4.24.35, gelatinase B, 92 kDa gelatinase, 92 kDa type IV collagenase, or PMNL gelatinase, polymorphonuclear leukocyte gelatinase, gelatinase type IV-B, collagenase type 5, collagenase-5, CL-5) (Tanaka et al, 1999; Baram et al, 2001; Yoshikawa et al, 1999; Vliagoftis, 2002; Fang et al, 1999)
¥ MMP-11 (matrix metalloproteinase-11, stromelysin-3, STMY3, SL-3, ST-3) (Tsuchiya S et al, 2009)
¥¥ MNSF-beta (monoclonal nonspecific suppressor factor, hNSF, NSF, Nonspecific suppressor factor, MNSF-beta, Fau protein, FAU, FAU1, Ubi-L, FBR-MuSV-associated ubiquitously expressed gene, Finkel-Biskis-Reilly murine sarcoma virus ubiquitously expressed, fox, dD3, asr1, arsenite resistance-1) receptors (Nakamura et al, 1994)
¥ MyD88 (Ho LH et al, 2007)

¥ neogenin (NGN, NEO1, neogenin-1) (Tsuchiya S et al, 2009)
¥ neurolysin (NLN, KIAA1226, EC3.4.24.16, AGTBP, Angiotensin-binding protein; angiotensin-2 binding protein, endopeptidase 24.16, endopeptidase 3.4.24.16; EP24.16, microsomal endopeptidase, MOP, Mitochondrial oligopeptidase M, neurolysin(24-16), NT endopeptidase, Neurotensin endopeptidase, Oligopeptidase M) (Piliponsky et al, 2008)
¥¥ Neuromedin B (NMB, ranatensin) receptors (Subramaniam et al, 2003)
¥¥ Neurotensin (NTS, NT, NT/NN, NT/N, Neuromedin N, NN, NMN) receptors (Miller et al, 1993; Carraway R et al, 1982; Piliponsky AM et al, 2008; Castagliuolo I et al, 1999; Feldberg et al, 1998)
¥ Nexin-1 (PN-1-alpha, Glial-derived neurite promoting factor, GdNPF, Glia-derived nexin, GDN, NPF, neurite-promoting factor, Serpin E2) (Tsuchiya S et al, 2009)
¥ NGF (nerve growth factor, 7S NGF, 7S nerve growth factor, NGF-alpha, Nerve growth factor-alpha, kallikrein Klk1b4, Klk1b4, NGF-beta, NGFB, Nerve growth factor-beta, NGFG, NGF-gamma, Nerve growth factor-gamma, kallikrein Klk1b3, Klk1b3) (Xiang and Nilsson, 2000; Skaper et al, 2001; Leon et al, 1994; Tam et al, 1997; Kurosawa et al, 1999; Zochodne and Cheng, 2000; Niyonsaba et al, 2010; Gelincik A et al, 2012)
¥¥ NGF (nerve growth factor, 7S NGF, 7S nerve growth factor, NGF-alpha, Nerve growth factor-alpha, kallikrein Klk1b4, Klk1b4, NGF-beta, NGFB, Nerve growth factor-beta, NGFG, NGF-gamma, Nerve growth factor-gamma, kallikrein Klk1b3, Klk1b3) receptors (NGFR, p75NTR, p75 neurotrophin receptor, p75LNGFR, p75NGFR, LNGFR, p75 low affinity NGF receptor, TNFRSF16, TNF receptor superfamily member 16, CD271, trkA) (Kim et al, 1999, 2008; Marshall et al, 1999; Welker et al, 1998; Bullock and Johnson, 1996; Kawamoto et al, 1995; Horigome et al, 1994; Kannan et al, 1993; Matsuda et al, 1991; Kambe et al, 2000; Tomioka et al, 1988; Brooks et al, 1999; Mazurek et al, 1986)
¥ NKEF-A (Natural killer enhancing factor A, Peroxiredoxin-1, PRDX1, PRX1, PAGA, proliferation-associated gene A, HBP23, heme-binding protein 23 kDa, MSP23, macrophage 23 kDa stress protein, PAG, proliferation-associated gene, AURA93, augmented in rheumatoid arthritis 93) (Tsuchiya S et al, 2009)
¥ NOD1 (Nucleotide-binding oligomerization domain protein 1, CARD4, caspase recruitment domain-containing protein-4, NLRC1, NLR family, CARD domain containing 1) (Feng et al, 2007)
¥ NOD2 (Nucleotide-binding oligomerization domain protein 2, CARD15, caspase recruitment domain-containing protein-15, NLRC2, NLR family, CARD domain containing 2, IBD1, inflammatory bowel disease 1, BLAU, CLR16.3) (Okumura et al, 2009; Wu et al, 2007)
¥ Notch-1 (Notch, Motch, Motch A, TAN-1, translocation-associated notch homolog-1) (Nakano et al, 2009; Tsuchiya S et al, 2009)
¥ Notch-2 (Motch B) (Nakano et al, 2009)
¥ Notch-4 (int-3) (Tsuchiya S et al, 2009)
¥ NRAGE (Neurotrophin receptor-interacting MAGE homolog, MAGED1, melanoma antigen family D1, Melanoma-associated antigen D1, Dlxin-1) (Tsuchiya S et al, 2009)
¥ NT-3 (neurotrophin-3, neuronotrophin-3, neurotrophic factor-3, NTF-3, HDNF, hippocampus-derived neurotrophic factor, NGF-2, Nerve growth factor-2) (Skaper et al, 2001; Tam et al, 1997)
¥¥ NT-3 (neurotrophin-3, neuronotrophin-3, neurotrophic factor-3, NTF-3, HDNF, hippocampus-derived neurotrophic factor, NGF-2, Nerve growth factor-2) receptors (trkC) (Metz et al, 2004)
¥ NT-4 (neurotrophin-4, neuronotrophin-4, neurotrophic factor-4) (Skaper et al, 2001)
¥ Nurr-1 (nuclear receptor-related factor 1, NR4A2, nuclear receptor subfamily 4 group A member 2, NOT, nuclear receptor of T-cells, TINUR, transcriptionally inducible nuclear receptor) (Zhang L et al, 2010)

¥¥ obestatin receptors (Hirayama et al, 2010)
¥ Oncomodulin (OCM, beta-parvalbumin, parvalbumin-beta, CBP-15, calcium binding protein 15) (Tsuchiya S et al, 2009)
¥ osteoglycin (OGN, OIF, osteoinductive factor, KSPG25, Mimecan, SLRR3A) (Tsuchiya S et al, 2009)
¥ osteopontin (OPN, OP, Osp, 2ar, 44 kDa bone phosphoprotein, 66 kDa bone phosphoprotein, bone sialoprotein, bone sialoprotein-1, BSP, BSP1, BSPI, Calcium oxalate crystal growth inhibitor protein, Eta-1, early T-lymphocyte activation protein 1, Nephropontin, Spp-1, Secreted Phosphoprotein-1, transformation-related phosphoprotein, tumor-secreted phosphoprotein, urinary stone protein, Uropontin) (Stelekati et al, 2009; Kunii et al, 2009)

¥ p75NTR (p75 neurotrophin receptor, p75LNGFR, p75NGFR, LNGFR, p75 low affinity NGF receptor, TNFRSF16, TNF receptor superfamily member 16) (Fischer et al, 2008)
¥¥ PACAP (pituitary adenylate cyclase-activating polypeptide, ADCYAP1, adenylate cyclase-activating polypeptide 1, PACAP(1-27), PACAP27, PACAP(1-38), PACAP38) receptors (Odum et al, 1998; Schmidt-Choudhury et al, 1999)
¥ PAI-1 (Plasminogen activator inhibitor-1, PAI, plasminogen activator inhibitor, endothelial plasminogen activator inhibitor, Serpin E1, MSF, monocyte suppressor factor, EIP-1, EGF-inducible protein 1, mesosecrin) (Wojta et al, 2002)
¥ PDCD4 (programmed cell death-4, MA-3, TIS, topoisomerase inhibitor-suppressed, H731, 197/15a, A7-1, DUG, death-upregulated gene) (Tsuchiya S et al, 2009)
¥ PDCD6 (programmed cell death-6, ALG2, Apoptosis-linked gene-2) (Tsuchiya S et al, 2009)
¥¥ PD-ECGF (platelet-derived endothelial cell growth factor, ECGF-1, endothelial cell growth factor-1, GLS, GLS/TP, Gliostatin, platelet-derived endothelial cell mitogen, EC2.4.2.4, thymidine phosphorylase, dThdPase, TYMP, Pyrimidine phosphorylase) receptors (Gruber et al, 1995)
¥ PDGF-A (platelet-derived growth factor-A Platelet-derived growth factor-1) (Nilsson et al, 1995)
¥¥ PDGF (platelet-derived growth factor, PDGF-1, PDGF-2, PDGF-A, PDGF-AA, PDGF-B, PDGF-BB, FDGF, fibroblast-derived growth factor, GDGF, glioma-derived growth factor-1, GDGF-2, glioma-derived growth factor-2, GSM, Glucocorticoid-suppressible mitogenic activity, MDF, mesangial cell proliferating factor, MDGF, monocyte-derived growth factor, OBIF, osteoblastogenesis inhibitory factor, ODGF, osteosarcoma-derived growth factor, T47D factor) receptors (PDGFR, PDGFR1, PDGFR2, PDGFRA, PDGFR-alpha, PDGFRB, PDGFR-beta, PDGF receptor, PDGF receptor-1, PDGF receptor-2, PDGF receptor-alpha, PDGF receptor-beta; patch; CD140a, CD140b, JTK12) (Gruber et al, 1995; Tsuchiya S et al, 2009)
¥ PDL2 (programmed death-1 ligand 2, PDCD1L2, PDCD1LG2, PDCD1 Ligand 2, B7-DC, Butyrophilin B7-DC, CD273) (Nakae et al, 2006)
¥ peroxisome proliferator-activated receptors (Sugiyama et al, 2000)
¥ PI9 (proteinase inhibitor-9, Serpin B9, CAP3, cytoplasmic antiproteinase 3, serine protease inhibitor-6, SPI-6) (Bladergroen et al, 2005)
¥ Plexin-B2 (PLXNB2, MM1, KIAA0315) (Tsuchiya S et al, 2009)
¥ PlGF (placenta growth factor, Placental growth factor, PGF, PlGF-1, placenta growth factor-1, PlGF-2, placenta growth factor-2) (Detoraki et al, 2009)
¥ proteinase-activated receptor-1 (PAR-1) (Vliagoftis, 2002; Gordon et al, 2000)
¥ proteinase-activated receptor-2 (PAR-2) (Kang et al, 2003; Mirza et al, 1997)
¥ proteinase-activated receptor-4 (PAR-4) (Kang et al, 2003)
¥ prothymosin-alpha (PTMA) (Tsuchiya S et al, 2009)
¥ PUMA (p53 upregulated modulator of apoptosis, BBC3, Bcl-2 binding component 3, JFY1) (Ekoff et al, 2007)
¥ PYPAF1 (Pyrin-containing APAF-1-like protein 1, NLRP3, NLR family, pyrin-domain containing 3, NALP3, NACHT-LRR-PYD-containing protein-3, CIS1, CIAS1, cold-induced auto-inflammatory syndrome, Cryopyrin, CLR1.1) (Kikuchi-Yanoshita et al, 2003; Nakamura Y et al, 2009; Ueno et al, 2008)

¥ RAGE (receptor for advanced glycosylation end products, AGER, advanced glycosylation end product-specific receptor) (Suzuki Y et al, 2008)
¥ RAMP-1 (receptor activity-modifying protein-1) (Tsuchiya S et al, 2009)
¥ RAMP-2 (receptor activity-modifying protein-2) (Tsuchiya S et al, 2009)
¥ Relaxin (RLN, RLX, RLN1, relaxin 1, relaxin H1, H1 relaxin, RLXH1, RXN1, RLN2, relaxin 2, relaxin H2, H2 relaxin, RLXH2, RXN2, relaxin 1/2) (Nakamura et al, 2002)
¥ retinoic acid receptors (Babina et al, 2001; Kinoshita et al, 2000)

¥¥ S1PR1 (sphingosine-1-phosphate receptor 1, S1P receptor 1, S1P1, Endothelial differentiation G-protein coupled receptor 1, EDG1, endothelial differentiation gene 1, CD363) (Jolly et al, 2004)
¥ S100A4 (S100 calcium binding protein A4, CAPL, calcium placental protein, Calvasculin, metastasin, metastasin-1, mts-1, 18A2, 42A, P9Ka, pEL98, fibroblast-specific protein 1, fibroblast secretory protein-1, FSP-1) (Tsuchiya S et al, 2009)
¥ S100A6 (S100 calcium binding protein A6, calcyclin, CACY, PRA, Prolactin receptor-associated protein, Growth factor-inducible protein 2A9) (Tsuchiya S et al, 2009)
¥ S100A10 (S100 calcium binding protein A10, Calpactin-1 light chain, CAL1L, Calpactin p11, CLP11, p11, 42C, NGF-induced protein 42C, Annexin-2 ligand, ANX2LG) (Tsuchiya S et al, 2009)
¥ SCF (stem cell factor, HLGF-1, hemolymphopoietic growth factor-1), kit ligand, KITL, KITLG, Mast/stem cell growth factor, MGF, mast cell growth factor, SLF, steel factor) (Welker et al, 1999; de Paulis et al, 1999; Ghannadan et al, 1998)
¥¥ SCF (stem cell factor, HLGF-1, hemolymphopoietic growth factor-1), kit ligand, KITL, KITLG, Mast/stem cell growth factor, MGF, mast cell growth factor, SLF, steel factor) receptors (kit, SCFR, CD117) (Bankl et al, 2001; Lora et al, 2003; Yang et al, 2003; Takeuchi et al, 2003; Matsuzawa et al, 2003; Saito et al, 1995; Shimizu et al, 2002; Ghannadan et al, 2002; Fang et al, 1999; Krauth et al, 2005; Schmidt-Choudhury et al, 1999; Djordjevic and Hanna, 2008; Kataoka et al, 2010; Matsuura J et al, 2010; Zhao W et al, 2008)
¥ Secretoneurin (SN, Chromogranin C, CHGC, SCG2, SgII, Secretogranin-2, gonadotrope polypeptide, GP-87, TSP86/84, tyrosine-sulfated protein 86/84 kDa) (Tsuchiya S et al, 2009)
¥ Semaphorin 4A (SEMA4A, Semaphorin B, SEMAB, Sem B) (Tsuchiya S et al, 2009)
¥ Semaphorin 7A (SEMA7A, Semaphorin L, SEMAL, H-Sema-L, H-Sema K1, Semaphorin K1, CD108, CDw108, JMH human blood group antigen) (Tsuchiya S et al, 2009)
¥ serglycin (SRGN, PRG1, PRG, PPG, platelet proteoglycan protein core) (Toyama-Sorimachi et al, 1997; Duelli et al, 2009; Braga et a, 2007; Ringvall et al, 2008; Abrink et al, 2004; Cho JJ et al, 1998; Eklung et al, 1997)
¥ Serpin B1 (LEI, Leukocyte elastase inhibitor, MNEI, monocyte neutrophil elastase inhibitor, ELANH2, Monocyte/neutrophil elastase inhibitor-2, EI, elastase inhibitor, L-DNase II, LEI-derived DNase II) (Yasumatsu et al, 2006)
¥ sFRP1 (secreted frizzled-related protein 1, FrzA, frizzled A, SARP-2, secreted apoptosis-related protein-2, FRP, frizzled-related protein) (Tsuchiya S et al, 2009)
¥ SIGLEC-5 (sialic acid binding immunoglobulin-like lectin 5, SIGLEC-F, CD33L2, CD33-like-2, OBBP2, Ob binding protein 2, CD170) (Yokoi et al, 2006)
¥ SIGLEC-6 (sialic acid binding immunoglobulin-like lectin 6, CD33 antigen-like, CD33L, CD33L1, Ob binding protein 1, OBBP1, CDw327, CD327) (Yokoi et al, 2006; Florian S et al, 2006)
¥ SIGLEC-8 (sialic acid binding immunoglobulin-like lectin 8, SAF-2, sialoadhesin family member 2) (Yokoi et al, 2006)
¥ SIGLEC-10 (sialic acid binding immunoglobulin-like lectin 10, CD330, SLG2, SIGLEC-like gene 2) (Yokoi et al, 2006)
¥ SLC25A4 (solute carrier family 25 member 4, ANT1, ADP/ATP translocase 1, Adenine nucleotide translocator 1, ADP/ATP translocator of skeletal muscle) (Tsuchiya S et al, 2009)
¥ SLC25A5 (solute carrier family 25 member 5 ANT2, ADP/ATP translocase 2, Adenine nucleotide translocator 2, ADP/ATP translocator of fibroblasts) (Tsuchiya S et al, 2009)
¥¥ somatostatin (SST, Somatotropin release inhibiting hormone, SIH, Somatotropin release inhibiting factor, SRIF, growth hormone-inhibiting hormone, GIH, growth hormone release inhibitory hormone, GH-RIH) receptors (Renold et al, 1987)
¥ Spred-1 (Sprouty-related EVH1 domain-containing protein 1) Wakioka et al, 2001)
¥ STIM1 (Stromal interaction molecule 1, GOK) (H‡jkov‡ Z et al, 2011)
¥ substance P (Neurokinin-1, NK1, NKA, Neurokinin A, Tac1, tachykinin-1) (Niyonsaba et al, 2010)
¥¥ substance P (Neurokinin-1, NK1, NKA, Neurokinin A, Tac1, tachykinin-1) receptors (van der Kleij et al, 2003; Azzolina et al, 2003; Kambe et al, 2001; Karimi et al, 2000; Cocchiara et al, 1999; Castagliuolo I et al, 1999; Brooks et al, 1999; Okayama et al, 1998; Ansel et al, 1993; Kulka et al, 2008; Okabe et al, 2006; Strik et al, 2007; McCary C et al, 2010; Asadi S et al, 2012)
¥ suppressin (SPN) (Ban and LeBoeuf, 1994)
¥ Swiprosin-1 (EFHD2, EF-hand domain containing protein D2) (Thylur et al, 2009; Ramesh TP et al, 2009)

¥ TFF-1 (Trefoil factor-1, breast cancer estrogen-inducible sequence, BCEI, gastrointestinal trefoil protein pS2, pS2) (Tsuchiya S et al, 2009)
¥ TFF-2 (Trefoil factor-2, spasmolytic protein, SML-1, spasmolysin) (Tsuchiya S et al, 2009)
¥ TGF-beta (transforming growth factor-beta, TGFB, B-TGF, Aqueous humor lymphocyte inhibitory activity, DIF, differentiation-inhibiting factor, EGI, epithelial cell-specific growth inhibitor; epithelial growth inhibitor, EIF, Epstein-Barr virus inducing factor, Epithelial cell growth inhibiting factor, G-TsF, glioma-derived T-cell suppressor factor, MDGF, milk-derived growth factor, MGF, milk growth factor, Polyergin, Simian BSC-1 cell growth inhibitor, SP factor, TCGF, transformed cell growth factor, TGI, tissue-derived growth inhibitor, TIF-1, tumor inducing factor-1) and/or receptors (Nilsson et al, 1995; Funaba et al, 2003; Boride et al, 1989; Gruber et al, 1994; Hu et al, 1994; Mekori and Metcalfe, 1994)
¥ TGF-beta-1 (TGFB1, transforming growth factor-beta-1, CIF-A, cartilage inducing factor A, ISF, immunosuppressive factor, MGF-b, milk growth factor, PDGI, platelet-derived endothelial cell growth inhibitor) (Vitsky et al, 2009)
¥¥ TGF-beta-1 (TGFB1, transforming growth factor-beta-1, CIF-A, cartilage inducing factor A, ISF, immunosuppressive factor, MGF-b, milk growth factor, PDGI, platelet-derived endothelial cell growth inhibitor) receptors (TGFBR1, TbetaRI, TbetaR1, transforming growth factor-beta receptor 1, TGF-beta receptor 1; TGF-beta receptor type 1, type 1 TGF-beta receptors, ALK5, Activin receptor-like kinase 5, activin A receptor type 2-like kinase, ACVRLK4, activin receptor-like kinase 4 ; TGFBR2, TbetaRII, TbetaR2, transforming growth factor-beta receptor 2, TGF-beta receptor 2, TGF-beta receptor type 2, type 1 TGF-beta receptors, MFS2, Marfan syndrome type 2) (Olsson N et al, 2000)
¥¥ TGF-beta-2 (transforming growth factor-beta-2, TGFB2, G-TsF, Glioblastoma-derived T-cell suppressor factor, CIF-B, cartilage inducing factor B, Corneal epithelial inhibitor of stromal cell collagenase synthesis, DSF, decidual suppressor factor, MGF-a, milk growth factor) receptors (TGFBR1, TbetaRI, TbetaR1, transforming growth factor-beta receptor 1, TGF-beta receptor 1; TGF-beta receptor type 1, type 1 TGF-beta receptors, ALK5, Activin receptor-like kinase 5, activin A receptor type 2-like kinase, ACVRLK4, activin receptor-like kinase 4 ; TGFBR2, TbetaRII, TbetaR2, transforming growth factor-beta receptor 2, TGF-beta receptor 2, TGF-beta receptor type 2, type 1 TGF-beta receptors, MFS2, Marfan syndrome type 2) (Olsson N et al, 2000)
¥¥ TGF-beta-3 (transforming growth factor-beta-3, TGFB3, ARVD1, Arrhythmogenic right ventricular cardiomyopathy type 1) receptors (TGFBR1, TbetaRI, TbetaR1, transforming growth factor-beta receptor 1, TGF-beta receptor 1; TGF-beta receptor type 1, type 1 TGF-beta receptors, ALK5, Activin receptor-like kinase 5, activin A receptor type 2-like kinase, ACVRLK4, activin receptor-like kinase 4 ; TGFBR2, TbetaRII, TbetaR2, transforming growth factor-beta receptor 2, TGF-beta receptor 2, TGF-beta receptor type 2, type 1 TGF-beta receptors, MFS2, Marfan syndrome type 2) (Olsson N et al, 2000)
¥¥ TGF-beta (transforming growth factor-beta, TGFB, B-TGF, Aqueous humor lymphocyte inhibitory activity, DIF, differentiation-inhibiting factor, EGI, epithelial cell-specific growth inhibitor; epithelial growth inhibitor, EIF, Epstein-Barr virus inducing factor, Epithelial cell growth inhibiting factor, G-TsF, glioma-derived T-cell suppressor factor, MDGF, milk-derived growth factor, MGF, milk growth factor, Polyergin, Simian BSC-1 cell growth inhibitor, SP factor, TCGF, transformed cell growth factor, TGI, tissue-derived growth inhibitor, TIF-1, tumor inducing factor-1) receptors (TGFBR1, TbetaRI, TbetaR1, transforming growth factor-beta receptor 1, TGF-beta receptor 1; TGF-beta receptor type 1, type 1 TGF-beta receptors, ALK5, Activin receptor-like kinase 5, activin A receptor type 2-like kinase, ACVRLK4, activin receptor-like kinase 4 ; TGFBR2, TbetaRII, TbetaR2, transforming growth factor-beta receptor 2, TGF-beta receptor 2, TGF-beta receptor type 2, type 1 TGF-beta receptors, MFS2, Marfan syndrome type 2) (Macey MR et al, 2010; Zhao W et al, 2008)
¥¥ Thrombin receptor (TR, CF2R, coagulation factor 2 receptor, F2R, PAR-1, Proteinase-activated receptor 1) (D'Andrea et al, 2000; Gordon et al, 2000; Nishikawa et al, 2000; Umarova et al, 2000; Zhang H et al, 2011; Zhang H et al, 2007)
¥ thrombospondin-2 (TSP2, THBS2) (Tsuchiya S et al, 2009)
¥ thymosin-beta-4 (TMSB4, TMSB4X, Tb4, Tbeta-4, 6-26, Fx, PTMB4, THYB4) (Tsuchiya S et al, 2009; Nemolato S et al, 2010)
¥¥ thymosin-beta-4 (TMSB4, TMSB4X, Tb4, Tbeta-4, 6-26, Fx, PTMB4, THYB4) receptors (Leeanansaksiri et al, 2004; Wycz—lkowska et al, 2007)
¥ Thymosin-beta-10 (TMSB10, Tbeta-10, Tb10, PTMB10, THYB10) (Tsuchiya S et al, 2009)
¥ thyroid hormone receptors (Tsuchiya S et al, 2009)
¥ Tim-1 (T-cell immunoglobulin and mucin domain-containing protein 1, T-cell membrane protein 1, TIMD1, HAVCR1, hepatitis A virus cellular receptor 1, HAVCR, hepatitis A virus cellular receptor, HAV receptor, KIM-1, Kidney injury molecule 1, Tapr, T-cell and airway phenotype regulator) (Nakae et al, 2007)
¥ Tim-3 (T-cell immunoglobulin and mucin domain-containing protein 3; T-cell membrane protein 3, T-cell immunoglobulin mucin 3, T-cell Ig mucin 3, Timd3, HAVCR2, hepatitis A virus cellular receptor 2) (Nakae et al, 2007; Wiener et al, 2007; Yoon SJ et al, 2011)
¥ TIMP-2 (tissue inhibitor of metalloproteinases-2, TIMP metallopeptidase inhibitor 2, CSC-21K, MI, CHIAMP, Chondrocyte-derived inhibitor of angiogenesis and metalloproteinase activity) (Inomata et al, 2005)
¥ TIMP-3 (tissue inhibitor of metalloproteinases-3, TIMP metallopeptidase inhibitor 3, mitogen-inducible gene 5, mig-5; SFD, Sorsby fundus dystrophy) (Tsuchiya S et al, 2009)
¥ TIMP-4 (tissue inhibitor of metalloproteinases-4, TIMP metallopeptidase inhibitor 4) (Koskivirta et al, 2006)
¥ TLR-1 (Toll-like receptor-1, rsc786, randomly sequenced cDNA 786, TIL, Toll-interleukin-1 receptor-like, CD281) (McCurdy et al, 2003)
¥ TLR-2 (Toll-like receptor-2, TIL-4, Toll-interleukin-1 receptor-like-4, Ly105, lymphocyte antigen 105, CD282) (McCurdy et al, 2003; Supajatura et al, 2001; Yoshioka et al, 2007; Inomata et al, 2005; Feng et al, 2007; Wu et al, 2007; Ršnnberg E et al, 2010)
¥ TLR-3 (Toll-like receptor-3, CD283) (Yang et al, 2009)
¥ TLR-4 (Toll-like receptor-4, human Toll, TOLL, Ly87, Rasl2-8, CD284) (Yoshikawa and Tasaka, 2003; Okumura et al, 2003; McCurdy et al, 2001; Supajatura et al, 2001; Mortaz et al, 2006)
¥ TLR-6 (toll-like receptor-6, CD286) (McCurdy et al, 2003; Supajatura et al, 2001)
¥ TLR-7 (Toll-like receptor-7) (Yang et al, 2009)
¥ TLR-8 (Toll-like receptor-8, CD288) (Supajatura et al, 2001)
¥ TLR-9 (Toll-like receptor-9, A6RP, A6-related protein, CD289) (Ikeda et al, 2003)
¥ TNF-alpha (tumor necrosis factor-alpha, TNFSF2, TNF ligand superfamily member 2, Cachectin, CF, cytotoxic factor, CTX, cytotoxin, DIF, differentiation inducing factor, EP, endogenous pyrogens, Hemorrhagic factor, Macrophage-derived cytotoxic factor, J774-derived cytotoxic factor, MCF, macrophage cytotoxic factor, MCT, macrophage cytotoxin, MD-FGF, monocyte-derived fibroblast growth factor, PCF, peritoneal cytotoxic factor, RCF, Released cytotoxic factor) (Azzolina et al, 2003; Kempuraj et al, 2003; Babina et al, 2004; Lorentz et al, 2003; Bullock and Johnson, 1996; Nilsson et al, 1995; Cocchiara et al, 1999; Okayama et al, 1998; Supajatura et al, 2002; Lorentz et al, 2000; Fang et al, 1999; Kulka et al, 2008; Mortaz et al, 2006; Cherwinski et al, 2005; Moulin D et al, 2007; Nakano et al, 2009; Bulanova et al, 2009; Schmidt et al, 2009; Ršnnberg E et al, 2010; Lappalainen J et al, 2011; Nagai K et al, 2012)
¥¥ TNF-alpha (tumor necrosis factor-alpha, TNFSF2, TNF ligand superfamily member 2, Cachectin, CF, cytotoxic factor, CTX, cytotoxin, DIF, differentiation inducing factor, EP, endogenous pyrogens, Hemorrhagic factor, Macrophage-derived cytotoxic factor, J774-derived cytotoxic factor, MCF, macrophage cytotoxic factor, MCT, macrophage cytotoxin, MD-FGF, monocyte-derived fibroblast growth factor, PCF, peritoneal cytotoxic factor, RCF, Released cytotoxic factor) receptors (CD120a, TNFRSF1A, TNF receptor superfamily member 1A, FPF, TNFAR, TNFR, TNFR1, TNFR55, TNFR60, TNFR-alpha, TNF receptor 1; CD120b, TNFRSF1B, TNF receptor superfamily member 1B, p75TNFR, TNFR2, TNFR75, TNFR80, TNFR-beta) (van Overveld et al, 1991; Kempuraj et al, 2005)
¥ TNF-beta (tumor necrosis factor-beta, TNFB, Coley's toxin, LT, lymphotoxin, lymphotoxin-alpha, LT-alpha, LTA, Necrosin, NKCF, natural killer cytotoxic factor, NK-CIA, Natural killer colony-inhibiting activity, TNFSF1, TNF ligand superfamily member 1) (Nilsson et al, 1995)
¥ thrombopoietin (TPO, THPO, c-MPL ligand, MPL ligand, ML, MGDF, megakaryocyte growth and development factor, Mk-CSF, megakaryocyte colony stimulating factor) receptors (MPL, TPOR, CD110) (Sawai et al, 1999)
¥ TRAIL (TNF-related apoptosis inducing ligand, APO-2 ligand, APO-2L, TL2, TNF-like-2, TNF ligand superfamily member 10, TNFSF10, Ly81, CD253) (Berent-Maoz B et al, 2010)
¥¥ TRAIL (TNF-related apoptosis inducing ligand, APO-2 ligand, APO-2L, TL2, TNF-like-2, TNF ligand superfamily member 10, TNFSF10, Ly81, CD253) receptor-2 (TRAIL receptor-2, TRAIL-R2, death receptor-5, DR5, KILLER, TRICK2, TRAIL receptor inducer of cell killing-2, TNFRSF10B, TNF receptor superfamily member 10B, CD262, Ly98) (Florian S et al, 2006)
¥ tristetraprolin (TTP, Nup475, nuclear protein-475, TIS11, TPA-inducible sequence-11, tetradecanoyl phorbol acetate-inducible sequence-11, TIS11a, TPA-inducible sequence-11, tetradecanoyl phorbol acetate-inducible sequence-11a, Zfp36, Zinc finger protein 36, GOS-24, G0/G1 switch gene 24) (Suzuki et al, 2003)
¥ TSG-6 (tumor necrosis factor-stimulated gene sequence-6, TNFAIP6, tumor necrosis factor-alpha-induced protein 6, TNFIP6, tumor necrosis factor-induced protein 6, PS4) (Nagyeri et al, 29011)
¥ TSLP (thymic stromal derived lymphopoietin, Thymic stromal lymphopoietin) (Okayama et al, 2009; Ying S et al, 2008)
¥¥ TSLP (thymic stromal derived lymphopoietin, Thymic stromal lymphopoietin) receptors (CRLF-2, cytokine receptor-like factor-2, Ly114, CRL2) (Okayama et al, 2009; Allakhverdi et al, 2007; Matsuda et al, 2010)

¥ urocortin (UCN, Urocortin-1, Urotensin-1) (Theoharides et al, 2009)

¥ VEGF-A (Vascular endothelial growth factor A; VEGF-1, vascular endothelial growth factor-1, VEGF, vascular endothelial growth factor; vasculo-endothelial growth factor, VEG/PF, vascular endothelial growth factor/vascular permeability factor, GD-VEGF, glioma-derived vascular endothelial growth factor, VAS, Vasculotropin, Vascular endothelial cell proliferation factor; VPF, vascular permeability factor, Mouse sarcoma 180-derived growth factor; FSdGF, Folliculo stellate cell-derived growth factor) (Nakasone et al, 2002; Feoktistov et al, 2003; Aoki et al, 2003; Boesinger et al, 1998; GrŸtzkau et al, 1998; Ribatti et al, 2001; Cao et al, 2006; Nakayama et al, 2004; Detoraki et al, 2009; Esposito I et al, 2004; Liang K et al, 2012; Delfino G et al, 2012)
¥ VEGF-121 (VEGF-A121, VEGF, vascular endothelial growth factor, VEGF-A, vascular endothelial growth factor A, VEGF-1, vascular endothelial growth factor-1, VEG/PF, vascular endothelial growth factor/vascular permeability factor, GD-VEGF, glioma-derived vascular endothelial growth factor, VAS, Vasculotropin, Vascular endothelial cell proliferation factor, VPF, vascular permeability factor, FSdGF, Folliculo stellate cell-derived growth factor) (Abdel-Majid RM and Marshall JS, 2004; GrŸtzkau A et al, 1989)
¥ VEGF-145 (VEGF-A145, VEGF, vascular endothelial growth factor, VEGF-A, vascular endothelial growth factor A, VEGF-1, vascular endothelial growth factor-1, VEG/PF, vascular endothelial growth factor/vascular permeability factor, GD-VEGF, glioma-derived vascular endothelial growth factor, VAS, Vasculotropin, Vascular endothelial cell proliferation factor, VPF, vascular permeability factor, FSdGF, Folliculo stellate cell-derived growth factor) (Abdel-Majid RM and Marshall JS, 2004)
¥ VEGF-165 (VEGF-A165, VEGF, vascular endothelial growth factor, VEGF-A, vascular endothelial growth factor A, VEGF-1, vascular endothelial growth factor-1, VEG/PF, vascular endothelial growth factor/vascular permeability factor, GD-VEGF, glioma-derived vascular endothelial growth factor, VAS, Vasculotropin, Vascular endothelial cell proliferation factor, VPF, vascular permeability factor, FSdGF, Folliculo stellate cell-derived growth factor) (Abdel-Majid RM and Marshall JS, 2004; GrŸtzkau A et al, 1989)
¥ VEGF-189 (VEGF-A189, VEGF, vascular endothelial growth factor, VEGF-A, vascular endothelial growth factor A, VEGF-1, vascular endothelial growth factor-1, VEG/PF, vascular endothelial growth factor/vascular permeability factor, GD-VEGF, glioma-derived vascular endothelial growth factor, VAS, Vasculotropin, Vascular endothelial cell proliferation factor, VPF, vascular permeability factor, FSdGF, Folliculo stellate cell-derived growth factor) (Abdel-Majid RM and Marshall JS, 2004; GrŸtzkau A et al, 1989)
¥ VEGF-206 (VEGF-A206, VEGF, vascular endothelial growth factor, VEGF-A, vascular endothelial growth factor A, VEGF-1, vascular endothelial growth factor-1, VEG/PF, vascular endothelial growth factor/vascular permeability factor, GD-VEGF, glioma-derived vascular endothelial growth factor, VAS, Vasculotropin, Vascular endothelial cell proliferation factor, VPF, vascular permeability factor, FSdGF, Folliculo stellate cell-derived growth factor) (Abdel-Majid RM and Marshall JS, 2004; GrŸtzkau A et al, 1989)
¥¥ VEGF-A (Vascular endothelial growth factor A; VEGF-1, vascular endothelial growth factor-1, VEGF, vascular endothelial growth factor; vasculo-endothelial growth factor, VEG/PF, vascular endothelial growth factor/vascular permeability factor, GD-VEGF, glioma-derived vascular endothelial growth factor, VAS, Vasculotropin, Vascular endothelial cell proliferation factor; VPF, vascular permeability factor, Mouse sarcoma 180-derived growth factor; FSdGF, Folliculo stellate cell-derived growth factor) receptors (Gruber et al, 1995; Detoraki et al, 2009)
¥ VEGF-B (vascular endothelial growth factor B, VEGF-B(167), VEGF-B(186), VRF, VEGF related factor, VRP, VEGF related protein) (Detoraki et al, 2009; Abdel-Majid RM and Marshall JS, 2004)
¥ VEGF-C (vascular endothelial growth factor C, VEGF-2, Vascular endothelial growth factor-2, flt-4 ligand, flt-4L) (Detoraki et al, 2009; Abdel-Majid RM and Marshall JS, 2004; Brideau G et al, 2007; Esposito I et al, 2004)
¥¥ VEGF-C (vascular endothelial growth factor C, VEGF-2, Vascular endothelial growth factor-2, flt-4 ligand, flt-4L) receptors (Detoraki et al, 2009)
¥ VEGF-D (vascular endothelial growth factor D, FIGF, fos induced growth factor) (Detoraki et al, 2009; Abdel-Majid RM and Marshall JS, 2004)
¥¥ VEGF-D (vascular endothelial growth factor D, FIGF, fos induced growth factor) receptors (Detoraki et al, 2009)
¥¥ VIP (vasoactive intestinal peptide) receptors (Goetzl et al, 1998; Kulka et al, 2008)

¥ Wnt-4 (SERKAL) (Tsuchiya S et al, 2009)

¥ XCL1 (chemokine C motif ligand-1, CL1, lymphotactin, Ltn, Lptn, SCM-1-alpha, Single C motif-1-alpha, ATAC, activation induced T-cell derived and chemokine related, SCYC1) (Rumsaeng et al, 1997)

For related information of interest see also: Cell types, Cell lines in Cytokine Research, Cell culture.

For other entries pertaining to hematopoiesis see also the Hematology Dictionary section of this encyclopedia.


Copyright © 2012 by H IBELGAUFTS. All rights reserved.
ENTRY LAST MODIFIED: December 2012



 

See REFERENCES for entry mast cells.

Click BACKLINKS to see which COPE entries contain the term mast cells .




COPE Homepage Top of Page


 
 
SUPPORT COPE | Intro | Subdictionaries | New Entries | Contribute data | COPE Credentials
# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

www.limes-institut-bonn.de Please inquire. COPE is interested in contacts with corporate sponsors appreciating and committed to communication biology

              Created, developed, and maintained by Prof Dr H Ibelgaufts              
About the author of COPE
  |    Contact COPE   |    Terms & Conditions


U L T R A   P O S S E   N E M O   O B L I G A T U R